CONFIDENTIAL

HOPON

(Hyperbaric Oxygen for the Prevention of Osteoradionecrosis):

A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated Mandible.

Study co-sponsors:

The University of Liverpool, Foundation Building, 765 Brownlow Hill, Liverpool L69 7ZX

Aintree University Hospitals NHS Foundation Trust Research & Development Room 2.06 Clinical Science Centre University Hospital Aintree Longmoor Lane Liverpool L9 7AL.

> EudraCT number: 2007-006225-27 Protocol version: 9 Date: 11th January 2017

Table of Contents

Ta	ble of Contents		
1.	List of Abbreviations and Definition of Terms	4	
2.	Study Protocol Approval	6	
Th	is protocol has been approved by:	6	
3.	Protocol Statements		
3.1.	Compliance with Good Clinical Practice		
3.2.	Registration of Study		
4.	Protocol Synopsis		
5.	Ethics		
5.1.	Independent Ethics Committees (IEC)		
5.2.	Ethical Conduct of the Trial		
5.3.	Patient Information and Informed Consent.		
6.	Study Administrative Structure		
6.1.	Investigators and Trial Centres		
6.1.			1
6.1.	5		
6.1.			
6.1.	4. Trial Steering Committee	13	3
6.1.	1 0		
6.1.			
6.1.			
6.1.			
6.1.			5
7.	Introduction and Rationale		
8.	Study Objectives		
8.1.	Outcome Measures		
8.1.			
8.1.			
8.1.	5)
9.	Investigational Plan		
0 1			
9.1.	Study Design		_
9.1.	1. Overall Design	20	
9.1. 9.1.	 Overall Design		1
9.1. 9.1. 9.1.	 Overall Design		1
9.1. 9.1. 9.1. 9.2.	 Overall Design	20 2 2 2	1
9.1. 9.1. 9.1. 9.2. 9.3.	 Overall Design	20 21 21 21	1 1
9.1. 9.1. 9.1. 9.2. 9.3. 9.3.	 Overall Design		1 1
9.1. 9.1. 9.2. 9.3. 9.3. 9.3.	 Overall Design Arm 1: Standard management¹⁹:		1 1 1
9.1. 9.1. 9.1. 9.2. 9.3. 9.3.	 Overall Design Arm 1: Standard management¹⁹:	20 27 27 28 29 29 20 20 20 20 20 20 20 20 20 20 20 20 20	1 1 1 1 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3.	 Overall Design		1 1 1 1 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 10.	 Overall Design		1 1 1 1 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3.	 Overall Design Arm 1: Standard management¹⁹:		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 10.	 Overall Design Arm 1: Standard management¹⁹:		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10. 10.1. 10.1	 Overall Design Arm 1: Standard management¹⁹:	20 21 21 21 21 21 21 21 21 21 21	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10. 10.1. 10.2.	 Overall Design Arm 1: Standard management¹⁹:	20 21 21 21 21 21 21 21 21 21 21	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3.	 Overall Design Arm 1: Standard management¹⁹:		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7	 Overall Design		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8	 Overall Design		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9	 Overall Design		1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9 11.	 Overall Design Arm 1: Standard management¹⁹:	20 21 21 21 21 21 21 21 21 21 21	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9	 Overall Design Arm 1: Standard management¹⁹: Arm 2: Standard management plus HBO¹ Time Schedule Criteria for Patient Selection Inclusion Criteria Exclusion Criteria Patient Screening Log Patient Screening Log Patient monitoring and criteria for withdrawal from treatment Investigational Products Investigational Medicinal Product Description Hyperbaric oxygen Packaging and Labelling of Investigational Products Administration of Investigational Products Treatment Assignment (Randomisation) Randomisation Code List Accountability for hyperbaric oxygen treatment Study Procedures and Assessments 	20 21 21 21 21 21 21 21 21 21 21	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9 11.	 Overall Design Arm 1: Standard management ¹⁹:	$\begin{array}{c} & & & & 2 \\ & & & & 2 \\ & & & & 2 \\ & & & &$	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9 11. X .	 Overall Design Arm 1: Standard management ¹⁹:	$\begin{array}{c} & & & & 2 \\ & & & & & 2 \\ & & & & & 2 \\ & & & &$	1 1 1 2 2
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9 11. X 12.	 Overall Design Arm 1: Standard management¹⁹:	$\begin{array}{c} & & & & 2 \\ & & & & & 2 \\ & & & & & 2 \\ & & & &$	1 1 1 1 2 2 3 7
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 10.1. 10.1. 10.2. 10.3. 10.4. 10.6 10.7 10.8 10.9 11. X 12.1.	 Overall Design	$\begin{array}{c} 22 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	1 1 1 1 2 2 3 7 7
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3	1. Overall Design 2. Arm 1: Standard management ¹⁹ . 3. Arm 2: Standard management plus HBO ¹ Time Schedule Criteria for Patient Selection 1. Inclusion Criteria 2. Exclusion Criteria 3. Patient Screening Log. 4. Patient monitoring and criteria for withdrawal from treatment Investigational Products. Investigational Medicinal Product Description 1.1. Hyperbaric oxygen Packaging and Labelling of Investigational Products. Preparation of Investigational Products. Administration of Investigational Products. Accountability for hyperbaric oxygen treatment Treatment Assignment (Randomisation) Randomisation Code List Accountability for hyperbaric oxygen treatment Treatment Compliance. Study Procedures and Assessments Safety Reporting Definitions: 1.1 1.2 Serious Adverse Event: 1.3 Serious Adverse Reaction (SAR)	$\begin{array}{c} 22 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	1 1 1 1 2 2 3 7 7 8
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3	 Overall Design	$\begin{array}{c} 22 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	1 1 1 1 2 2 3 7 7 8
9.1. 9.1. 9.2. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3. 9.3	1. Overall Design 2. Arm 1: Standard management ¹⁹ . 3. Arm 2: Standard management plus HBO ¹ Time Schedule Criteria for Patient Selection 1. Inclusion Criteria 2. Exclusion Criteria 3. Patient Screening Log. 4. Patient monitoring and criteria for withdrawal from treatment Investigational Products. Investigational Medicinal Product Description 1.1. Hyperbaric oxygen Packaging and Labelling of Investigational Products. Preparation of Investigational Products. Administration of Investigational Products. Accountability for hyperbaric oxygen treatment Treatment Assignment (Randomisation) Randomisation Code List Accountability for hyperbaric oxygen treatment Treatment Compliance. Study Procedures and Assessments Safety Reporting Definitions: 1.1 1.2 Serious Adverse Event: 1.3 Serious Adverse Reaction (SAR)	$\begin{array}{c} & & & & & & & \\ & & & & & & \\ & & & & & \\$	1 1 1 1 2 2 3 7 7 8

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

EudraCT Number: 2007-006225-27	Version:9 11/01/2017
12.3.1. Adverse Events	
12.3.2. Serious Adverse Event Reporting	
12.3.3. Suspected Unexpected Serious Adverse Reaction (SUSAR)	
12.3.4. Annual Reporting to MHRA and MREC	
13. Quality Assurance/Audit	
13.1. Quality control	
13.2. Risk assessment	
14. Confidentiality	
15. Case Report Forms and Data Handling	
15.1. Case Report Forms	
15.2. Data Handling	
16. Protocol Amendments	
17. Agreements	
17.1. Research Site Agreement	
Completion of Trial	
17.2. Trial Completion Procedures	
17.3. Archiving of Trial Documents	
18. Statistical Considerations	
18.1. Introduction	
18.2. Blinding	
18.3. Missing Data	
18.4. Sample Size	
18.5. Patient Accrual	
18.6. Statistical Analysis Plan	
18.7.1. Patient Groups for Analysis	
18.7.2. Handling of mis-randomised patients and dropouts	
18.7.3. Identification and Handling of outliers	
18.7.4. Study centre effects	
18.7.5. Adjustment for covariates	
18.7.6. Multiplicity adjustments	
18.7.7. Missing data	
18.7.8. Sensitivity analyses	
18.7.9. Prespecified subgroup analyses	
18.7.10. Assessment of study quality & compliance	
18.7.11. Definitions & Derived variables	
18.7.12. Description of baseline subject characteristics	
18.7.13. Specification and estimation of efficacy parameters	
18.8. Analysis of primary outcome	
18.8.1. Test of efficacy	
18.8.2. Tests of assumptions	
No specific tests of assumptions for the primary endpoint are planned	
18.8.3. Analysis of secondary outcomes	
18.8.4. Analysis of safety	
18.9. Interim analysis and data monitoring committee	
19. Use of information	
20. Publications	
21. Contact numbers for the randomisation centre and Investigation	

1. List of Abbreviations and Definition of Terms

Abbreviation Abbreviated term

AE	Adverse Event
AL	Adverse Event Atmosphere Absolute Pressure
AUC	Area Under Curve
CC	Clinical Coordinator
CI	Chief Investigator
CRF	
	Case Report Form
CR-UK	Clinical Tricle Advisory & Awards Committee
CTAAC	Clinical Trials Advisory & Awards Committee
CTCAE	Common Toxicity Criteria for Adverse Events
CV	Curriculum Vitae
DNA	Deoxyribonucleic Acid
EDTA	Ethylene-diamineteraacetic acid
EORTC	European Organisation for Research and Treatment of Cancer
EU	European Union
FSC	Feasibility Study Committee
GCP	Good Clinical Practice
GMP	Good Manufacturing Practice
Gy	Dose of radiotherapy in Grays
HBO	Hyperbaric Oxygen
HN CSG	Head & Neck Cancer Clinical Studies Group
ICH	International Conference on Harmonisation
IDSMC	Independent Data and Safety Monitoring Committee
IEC	Independent Ethics Committee
IMP	Investigational Medicinal Product
IMRT	Intensity Modulated Radiotherapy
ITT	Intention to Treat
IV	Intravenous
LCTU	Liverpool Cancer Trials Unit
LECMC	Liverpool Experimental Cancer Medicine Centre
LREC	Local Ethical Research Committee
MBS	Minor Bone Spicules
mg	Milligram
MHRA	Medicines and Healthcare Products Regulatory Agency
min	Minimum
ml	Millilitre
MRC	Medical Research Council
NCI	National Cancer Institute
NCRI	National Cancer Research Institute
NHS	National Health Service
NNT	Number Needed to Treat
NRES	National Research Ethics Service
OPT	Orthopantomogram

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

EudraCT Number:	: 2007-006225-27
ORN	Osteoradionecrosis
PI	Principal Investigator
QA	Quality Assurance
QC	Quality Control
QLQ	Quality of Life Questionnaire
QoL	Quality of Life
R&D	Research and Development
RCT	Randomised Controlled Trial
RSI	Reference Safety Information
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SmPC	Summary of Product Characteristics
SOP	Standard Operating Procedure
SUSAR	Suspected Unexpected Serious Adverse Reaction
TC	Trial Coordinator
TSC	Trial Steering Committee
UK	United Kingdom
UoW	University of Washington
VAS	Visual Analogue Scale
WHO	World Health Organisation

EudraCT Number: 2007-006225-27 2. Study Protocol Approval

I, the undersigned	, hereby app	prove this cli	nical study proto	ocol:
ł	6			
Signature:	la	~		
Prof Richard Shav	v, Chief Inv	restigator		
	Λ	A		
Signature:	A.	1627		

Signed on behalf of the University of Liverpool

Signature:

Signed on behalf of the Aintree University Hospitals NHS Foundation Trust

Signature:

Professor J. Neoptolemos, Director of the Cancer Research UK Liverpool Cancer Trials Unit

This protocol has been approved by:

- The Chief Investigator
- The University of Liverpool
- Aintree University Hospitals NHS Foundation Trust
- The Director of the Cancer Research UK Liverpool Cancer Trials Unit

Version:9 11/01/2017

Date: 22 MM (7 -

Date: 24 AN

Date: 24/Mar/17

Date: 31 3117.

6

3. Protocol Statements

3.1. Compliance with Good Clinical Practice

This Study Protocol is designed to comply with the Guideline established by the International Conference on Harmonisation (ICH) on the topic Good Clinical Practice (GCP) and published by the European Agency for the Evaluation of Medicinal Products as "Note for Guidance on Good Clinical Practice" (CPMP/ICH/135/95) (Approval 17 July 1996) as well as other relevant guidelines issued by ICH, primarily the efficacy, safety and ethical guidelines.

3.2. Registration of Study

This study will have National Research Ethics Service (NRES) approval and hold a Clinical Trials Authorisation issued by the Medicines and Healthcare Products Regulatory Agency (MHRA). Each centre must undergo Site Specific Assessment by the relevant Local Ethical Research Committee (LREC) and must be granted Research and Development Approval from each Trust where the trial will be carried out.

4. Protocol Synopsis

Investigational Medicinal Product (IMP):	Hyperbaric Oxygen (HBO) Treatment
Title of Study/ Protocol Number:	A phase III randomised controlled study investigating Hyperbaric Oxygen to Prevent Osteoradionecrosis (ORN) of the Irradiated Mandible.
Chief Investigator:	Professor Richard Shaw
Number of Study Centres and Distribution:	19 centres within the UK, four centres internationally.
Study Period:	May 2010 until February 2018.
Main Objective(s):	 To determine the benefit of HBO in the prevention of osteoradionecrosis (ORN) subsequent to a surgical procedure in the "at risk" irradiated mandible. Questions in a number of key areas will be addressed by this trial: 1. Incidence of ORN in at risk procedures without HBO – published rates vary between 0 and 30%. 2. Outcome of ORN cases without HBO. 3. Benefit of HBO: a. What proportion of the risk of ORN might be prevented by HBO treatment? b. If not totally prevented, is the severity affected i.e. the distribution amongst grades <i>l</i>(<i>II</i>/<i>III</i> different between HBO and non-HBO arms? 4. Morbidity of HBO: measurement of adverse events in treatment arm related to hyperbaric oxygen treatment 5. Acceptability of Randomisation: to determine if clinicians / patients consent to recruitment for a HBO randomised control trial.
Methodology:	This study is designed as a phase III randomised control multi-centre study.
Translational study:	The translational element of the trial will involve the collection and storage of blood samples and will aim to identify biomarkers of risk of developing ORN or response to HBO treatment.
	The sample collection for each patient in each arm of the study is as follows:
	Blood sample x 1 – 6 ml venous blood 6ml standard EDTA tube
	All samples will be sent via pre-labelled 1 st class postage to Liverpool Experimental Cancer Medicine Centre

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

221

Version:9 11/01/2017 (LECMC) Good Clinical Laboratory Practice (GCLP) compliant labs at the University of Liverpool where they will be received and managed by an ECMC laboratory technician.

Number of Patients to be Enrolled:

Duration of Treatment:

This trial has a run-in-period (of up to four weeks) before randomisation, where all volunteers attend the assessment centres for trial eligibility assessment, consent procedure and advice regarding management of their condition. During this time volunteers will be assessed to confirm potential suitability for hyperbaric oxygen therapy. Then patients will be randomised to either:

5. Ethics

5.1. Independent Ethics Committees (IEC)

The protocol and relevant amendments must be approved by/receive favourable opinion from National Research Ethics Service (NRES) and Medicines and Healthcare Products Regulatory Agency (MHRA). Each UK NHS centre must receive approval to participate in the trial from MREC, MHRA and the relevant NHS R&D department before carrying out trial related activities. Non-NHS centres must receive approval from the MHRA and undergo Site Specific Assessment by the relevant Local Ethical Research Committee (LREC) and written evidence of approval must be made available to the Central Trials Office, CR-UK Liverpool Cancer Trials Unit (LCTU) prior to enrolment of subjects. The study may only commence when approval is granted.

5.2. Ethical Conduct of the Trial

The trial will be conducted to conform to the principles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly, 1964, and subsequent amendments (Tokyo (1975), Venice (1983), Hong Kong (1989) and South Africa (1996).

The study will be conducted in accordance with the EU Directive 2001/20/EC, the Medicines for Human Use (Clinical Trials) Regulations 2004 and the principles of Good Clinical Practice.

Patients will be asked to consent that data are recorded, collected, stored and processed and may be transferred to other countries within and outside the EU, in accordance with any national legislation implementing the EU Data Protection Directive (95/46/EC).

This study may be terminated at the request of the Chief Investigator, Independent Data and Safety Monitoring Committee, Independent Ethics Committee or the MHRA if, during the course of the study, concerns about the safety of further dosing emerge.

The Chief Investigator will update the ethics committee of any new information related to the study drug when appropriate.

EudraCT Number: 2007-006225-275.3. Patient Information and Informed Consent

The consent process must be carried out by a medically or dentally qualified member of the research team. All patients will receive written and verbal information concerning the nature of the study, the known side effects that they might expect and the risks. This information will emphasise that participation in the trial is voluntary and that the patient may withdraw from the trial at any time and for any reason. All patients will be given opportunity to ask questions and will be given sufficient time to consider before consenting.

Both the clinician taking consent and the patient must personally sign and date the form. The original copy of the signed Consent Form will be retained by the Investigator in the Study File. A copy will also be filed in the subject's notes and a further copy of the signed Consent Form will be given to the subject.

The patient's signed and dated informed consent to participate in the trial must be obtained **prior** to any trial related procedure and randomisation being carried out.

6. Study Administrative Structure

6.1. Investigators and Trial Centres

6.1.1. Chief Investigator

The Chief Investigator is responsible for approval of the protocol, CRF and the clinical report on behalf of all study investigators.

Professor Richard Shaw

Professor of Head & Neck Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool Honorary Consultant in Oral & Maxillofacial Surgery, University Hospital Aintree, Liverpool Email: richard.shaw@liverpool.ac.uk

6.1.2. Working Group

The HOPON Working Group will be responsible for day-to-day management of the study.

Professor Richard Shaw As above

Mr. Binyam Tesfaye Clinical Trial Coordinator

Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool 1st floor Block C, Waterhouse Building 3 Brownlow Street Liverpool L69 3GL

Tel: +44 (0)151 794 8245 Fax: +44 (0)151 794 8931 Email: btesfaye@liv.ac.uk

Dr Paul Silcocks

Trial Statistician Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool Cancer Research Centre University of Liverpool Block C Waterhouse Building 1-3 Brownlow Street L69 3GL

T: 0151 7948802 F: 0151 794 8930 E: paul.silcocks@liverpool.ac.uk

Mr Matthew Bickerstaff

Senior Trial Co-ordinator Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool Block C Waterhouse Building 1-3 Brownlow Street L69 3GL Tel: (00 44) 151 794 8934 Fax: (00 44) 151 794 8931 Email: hopon@liv.ac.uk

Mr Christopher J Butterworth

Honorary Senior Lecturer/Consultant in Oral Rehabilitation Regional Maxillofacial Unit Liverpool University Dental Hospital The School of Dental Sciences Pembroke Place Liverpool L3 5PS Tel: 0151 706 5205 Fax: 0151 706 5797 Email: Christopher.Butterworth@rlbuht.nhs.uk

Dr Seema Chauhan

Operational Director Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool Block C Waterhouse Building 1-3 Brownlow Street L69 3GL Tel: 0151 794 8938 Fax: 0151 794 8930 Email: chauhans@liv.ac.uk

Dr Aditya Shenoy

Clatterbridge Centre for Oncology Clatterbridge Road Bebington Wirral CH63 4JY Tel: 0151 482 7697 (sec) Fax: 0151 482 7621 Email: aditya.shenoy@clatterbridgecc.nhs.uk

6.1.3. Independent Safety Data Monitoring Committee

The Independent Safety Data Monitoring Committee (ISDMC) will be responsible for reviewing and assessing recruitment, interim monitoring of safety, trial conduct and external data. Further to this, they will provide a recommendation to the Trial Steering Committee concerning the continuation of the study.

The ISDMC consists of an independent Clinical Oncologist, Head and Neck Surgeon and an independent Statistician, also expert in the field of oncology as below:

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

Mr Gerry Robertson

Consultant in Clinical Oncology Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, Tel:0141 301 7000 E-mail: andrew286robertson@btinternet.com

Mr Jeremy McMahon

Consultant Oral & Maxillofacial Surgeon Southern General Hospital 1345 Govan Road Glasgow G51 4TF Tel: 0141 201 1100 E-mail: Jeremy.McMahon@ggc.scot.nhs.uk

Mr Jim Paul

Head of Biostatistics Cancer Research UK Clinical Trials Unit, Glasgow The Beatson West of Scotland Cancer Centre Level 0, 1053 Gt. Western Road Glasgow, G12 0YN Tel: 00 44 (0) 141 301 7188 Fax: 00 44 (0) 141 301 7189 E-mail: j.paul@clinmed.gla.ac.uk

6.1.4. Trial Steering Committee

Dr Richard Simcock

Consultant Clinical Oncologist Lead Clinician for Breast Care Sussex Cancer Centre Eastern Road Brighton BN2 5BE Tel: 01273 696955 Ext 4328 Email: Richard.Simcock@bsuh.nhs.uk

Dr Mark Glover

Principal Consultant Hyperbaric Medicine Hyperbaric Medicine Unit Spitalfield Lane Park Chichester West Sussex PO19 6SE Tel: 01243 776621 Fax: 01243 775341 Email: MAGLOVER1@qinetiq.com HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

Dr Syed Hussain

Clinical Senior Lecturer in Medical Oncology Department of Molecular and Clinical Cancer Medicine University of Liverpool 5th Floor UCD Duncan Building Daulby Street Liverpool L69 3GA Tel: 0151 706 4177 Fax: 0151 706 5826 Email: Syed.Hussain@liv.ac.uk

Mrs Sarah Brown

Senior Medical Statistician Clinical Trials Research Unit University of Leeds Clinical Trials Research House 71-75 Clarendon Road Leeds LS2 9PH Tel: 0113 343 1472 Fax: 0113 343 1471 Email: s.brown@leeds.ac.uk

Mr Richard Shaw

As above

Mr Matthew Bickerstaff As above

Mr Binyam Tesfaye As above

Mr Dominic Macareavy

Independent Lay Member Merseyside Regional Head and Neck Cancer Centre University Hospital Aintree Lower Lane Liverpool L9 7AL Email: Dominic.Macareavy@BLM-LAW.COM

Mr John Richardson

Independent Lay Member 851 Liverpool Road Southport PR8 3NX Tel: 01704 573136 Email: jdd_bfgc@tiscali.co.uk The Trial Steering Committee (TSC) will be responsible for monitoring and supervising the progress of the trial, reviewing data from other studies, resolving issues related to trial design, trial conduct and reporting and considering the recommendations of the ISDMC.

6.1.5. Principal Investigators

Each participating Principal Investigator (PI) will be responsible for all aspects of trial conduct at his/her site as agreed to in the Research Site Agreement, to be signed prior to trial initiation. Each PI will also be provided with details on how and when to report Serious Adverse Events in their Investigator Site File.

6.1.6. Sub-Investigators

Each participating sub-investigator will be responsible for aspects of trial conduct delegated to him/her by the PI at their site as described in the delegation log, to be signed prior to trial procedures performed by the sub-investigator.

6.1.7. Co-Investigators

Participating co-investigators are researchers who will provide significant intellectual input into the research and will be responsible for the day to day running of some aspects of the trial conduct.

6.1.8. Sponsor

The study is co-sponsored by:

Aintree University Hospitals NHS Foundation Trust Research & Development Room 2.06 Clinical Science Centre University Hospital Aintree Longmoor Lane Liverpool L9 7AL The University of Liverpool, Foundation Building, 765 Brownlow Hill, Liverpool L69 7ZX

6.1.9. Trial Statistician

The trial statistician will input into the development of the protocol and provide advice on trial design, randomisation procedure, Case Report Form (CRF) and database design. The trial statistician will plan and undertake all interim and final analyses of the trial data reporting results to the ISDMC and will prepare results for presentation and publications.

Dr Paul Silcocks Trial Statistician Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool Cancer Research Centre University of Liverpool Block C Waterhouse Building 1-3 Brownlow Street L69 3GL EudraCT Number: 2007-006225-27 Tel: 0151 7948802 Fax: 0151 794 8930 Email: paul.silcocks@liverpool.ac.uk

7. Introduction and Rationale

Background

The most feared complication of radiotherapy for head and neck cancer is osteoradionecrosis (ORN) of the jaws. ORN describes the process where irradiated bone undergoes necrosis and becomes exposed through the investing soft tissues for a period of at least 3 months. The most important risk factor for ORN is surgical trauma, commonly dental extractions in an irradiated jaw, but ORN can also occur spontaneously. ORN is painful and debilitating, sometimes requiring surgical resection of the jaw and/or hyperbaric oxygen (HBO) treatments. The morbidity and mortality of ORN is significant and treatment outcomes often unsatisfactory. As such, much attention has been given to methods of prevention. These include pre-radiotherapy extraction of teeth and the use of HBO treatments or prophylactic antibiotics for post-radiotherapy extractions.

The overall incidence of ORN among post-radiotherapy patients is not certain but may have declined³ with improvement of radiotherapy techniques in recent decades. However the most recent changes in delivery of radiotherapy, in particular the rise in popularity of organ preservation, concomitant chemoradiotherapy and IMRT (intensity modulated radiotherapy) might reasonably be expected to increase the rate of ORN in the future.

The dose of radiotherapy is an important risk factor for the development of ORN. Most cases of ORN occur after doses >60 Gy and few cases occur after doses <50Gy. The risk of ORN is considered greater with post- than with pre- radiotherapy extractions. The incidence of ORN is higher in the posterior mandible compared with the maxilla or anterior mandible which is attributed to its relatively poor blood supply. Alcohol or tobacco use, although common in head and neck cancer patients, does not seem to be a direct cause of osteoradionecrosis. Poor dental health before radiotherapy may cause later ORN and clearly there is a case for thorough dental inspection and treatment prior to radiotherapy. This is not always achieved and also post-radiation oral changes often cause serious deterioration in dental health. Post radiation extractions should be performed atraumatically and antibiotics are commonly prescribed^{4.}

There have only been limited studies of prophylactic HBO. In a randomised, prospective study⁵, showed a significantly lower incidence of ORN after post radiotherapy dental extractions in the HBO group when compared with the control group. There were 2 cases of ORN in 37 patients (5.4%) receiving HBO undergoing 156 extractions, compared with 11 cases in 37 patients (29.9%) undergoing 135 extractions receiving prophylactic penicillin, resulting in a number needed to treat (NNT) of 4. This single trial was carried out within one US unit and was unblinded. Vudiniabola *et al*⁶ showed that of 29 patients who received pre-extraction HBO, 1 (3.4%) developed ORN; and of 7 patients who did not receive HBO, 1 (14.3%) developed ORN. On the basis of these two small studies, many dentists and surgeons have prescribed prophylactic HBO to prevent ORN in post radiotherapy extraction patients. Prophylactic HBO therapy has become the "treatment of choice"⁷; the "optimum management"⁸ for the prevention of ORN.

Hyperbaric oxygen therapy is a time-consuming and relatively costly process (approx £3000 per course in Merseyside for NHS patients, this excluding patient costs such as transport & loss of income). The typical protocol calls for 30 hours of preoperative treatment in 20 90-minute sessions in a hyperbaric chamber, followed by 15 hours of postoperative treatment in 10 90-minute sessions. A doctor, medical assistant and technical staff, are required for each session. There are risks associated with HBO therapy. One study of 90 HBO patients recorded serious adverse events, including seizure (3.4%), stroke (1.1%), and myocardial infarction (1.1%)⁹. There were also cases of eustachian tube dysfunction requiring HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document 16

myringotomy (2.2%). The overall incidence of complications of HBO was 7.8%. Subsequent series have, however, reported much lower complication rates and this impression has been confirmed by more reassuring safety data from the British Hyperbaric Association. The most comprehensive recent review¹⁰ cites 33 research papers. This review estimates the risks as temporary visual problems "common", Eustachian tube problems 2%, claustrophobia 2%, seizure <0.01%, and MI and stroke are not considered to be risks as such. There is a theoretical risk of decompression sickness if decompression occurs uncontrollably and a risk of explosion both from the oxygen-rich environment of the hyperbaric chamber and the pressure of the chamber itself.

In addition to the potential for adverse events associated with HBO, retrospective evidence offers contradictory data regarding any protective benefits. Sulaiman et al¹¹ review a series of 180 consecutive dental extractions in a 3 year period amongst the irradiated population of Memorial Sloan-Kettering without the use of HBO. They report only 4 cases of ORN (2.2%), although it is important to note that the favourable socioeconomic profile and oral hygiene / compliance of that particular population is likely to be atypical of the general head and neck squamous cell carcinoma population. A simple pooling performed by Wahl¹² of 8 published retrospective studies of dental extractions without HBO from 1986-2005 (including Sulaiman) finds 16 cases of ORN from 461 extractions (3.5%), advising that prophylactic HBO should be reconsidered.

A postal questionnaire¹³ of UK practice reveals that, in the management of "at risk" extraction of a lower molar in an irradiated mandible, 33% "never", 41% "sometimes" and 26% "usually" / "always" prescribe prophylactic HBO. This highlights the current state of equipoise in the UK. A questionnaires of attitude to RCTs for HBO¹⁴ revealed that 93% of responders would wish to recruit such patients into a NCRI/Cancer Research UK backed trial.

With regard to implant placement, the case for HBO is made both on the basis of ORN and a potential beneficial effect on implant survival. A retrospective series¹⁵ of 172 osseointegrated implants placed in 38 irradiated patients was performed. Implant loss was not influenced by HBO (HBO:19% vs No HBO:18%). Potential confounding variables were explored but were not biased between the groups. ORN was seen at a frequency of 6% but only occurred in patients treated with HBO. Schoen (*Oral Oncol.* 2006 Sep 21) reported on 26 similar patients, 13 of whom received HBO. Implant loss was actually higher in the HBO group (14.8% vs 6.1%) with one case of ORN occurring in the HBO group. In contrast, Granstrom¹⁶ reported HBO significantly improved implant survival in a case-control study of irradiated bone from 34 of 43 implants lost to 5 of 42 lost (P =0.008). Further work by Granstrom¹⁷ reinforced these earlier data finding that treatment with HBO reduced the implant failure rate.

There has also been considerable previous interest in a RCT for the treatment of established ORN using HBO within the National Cancer Research Institute (NCRI) Head & Neck Clinical Study Group (NCRI HN CSG). The considerable difficulties in trial design have been emphasised by the RCT published by Annane et al¹⁸. This study is notable for its double blind design, controversially using "sham" hyperbaric oxygen as placebo. The data appear to show that at least 75% of the treatment group failed to receive the protocol minimum 30 treatments. At one year, the recovery in the HBO arm was 19.3% and 32.4% in the placebo arm. The fact that the trial ended early under the protocol stopping rules must question the value of therapeutic HBO for established ORN. Many have questioned the relevance of this study in attempting to use HBO alone: Marx had suggested HBO as an adjunct to appropriate surgery. In closing the trial, one might assume that the issue of HBO in ORN had been settled. In the UK, however, considerable debate ensued, both published¹⁹ and within the NCRI HN CSG. It was felt that this study highlighted the need for adequately funded, robust, randomised trials of HBO in the UK backed by the NCRI.

Rationale for the study

Version:9 11/01/2017

Following discussion within the NCRI HN CSG, it was apparent that the area of greatest polarisation regarding treatment protocols, but also agreement as to a satisfactory trial design, was in the area of prophylactic HBO. A randomised trial in the prophylactic use for all indications was conceived i.e. dental extractions, implant placement & other forms of surgery in the at risk jaw. Unfortunately, hyperbaric oxygen protocols have evolved with some differences around the UK. An early assurance has been gained from all HBO chambers that a protocol consistent with Marx's original protocol based around a version of Royal Navy Therapeutic table no. 66 which will be uniformly applied in the trial. A Cancer Research UK Feasibility Study Committee (FSC) application was thus developed. The original FSC study has now been extended into a full phase III Clinical Trials Awards and Advisory Committee (CTAAC) application. This phase III trial has been designed to incorporate the data generated by the pilot. An appropriate statistical adjustment (such as Fisher's combination test) would be used to preserve the overall type I error rate when combining the data across the two phases.

The clinical review period is one year in order to detect any differences in the severity and course of osteoradionecrosis encountered in each arm. This allows the rate of implant retention to be more realistically measured where appropriate.

The health economics of HBO are also pertinent. HBO costs around £3000-£6000 per treatment course in the UK and currently this expense is being actively questioned by NHS funding bodies in the absence of adequate data. A detailed cost analysis will be generated by this phase III trial. This will weigh the extra expense of treating excess ORN cases with that of extending HBO more widely in the preventative setting.

8. Study Objectives

Questions in a number of key areas are addressed by this trial:

- 1. **Incidence of ORN:** what is the incidence of ORN following 'at risk' procedures, and how is this affected by the use of prophylactic HBO?
- 2. **Outcome of ORN**: what proportion of ORN cases progress to the most serious outcomes, and how is this influenced by the use of prophylactic HBO?
- 3. Morbidity of HBO: measurement of adverse events in treatment arm related to HBO therapy.
- 4. Cost effectiveness: what is the financial justification for prophylactic HBO in this setting?
- 5. **Oral rehabilitation:** how is osseointegrated implant retention affected by HBO independent of any effect on the incidence if ORN?
- 6. Late follow up of MBS (Minor Bone Spicules) to assess risk of further deterioration for patients with MBS (see Appendix 11)
- 7. Late follow up of implant survival: How many implants were lost since completing the HOPON assessments? (See Appendix 12).

8.1. Outcome Measures

8.1.1. Primary Outcome:

The presence of osteoradionecrosis at 6 months after surgery defined according to the Chief Investigator's revised criteria (see appendix 9), as determined by blinded central review of Clinical photograph, Radiography and PI assessment (see algorithm, appendix 10).

8.1.2. Secondary Outcomes:


- 1. The diagnosis of osteoradionecrosis at 3 and 12 months (in the same way as the 6 month outcome)
- 2. Severity of cases of diagnosed osteoradionecrosis, according to Notani grade
- 3. Pain: patient questionnaire at baseline, 3, 6 and 12 months
- Quality of life (QoL): following randomisation, and at 3, 6 and 12 months following surgery (as determined by a modified University of Washington Head and Neck QoL questionnaire Appendix 6)
- 5. Implant survival and outcome of MBS

8.1.3. Safety Outcomes:

- 1. Adverse events in HBO arm related to hyperbaric oxygen treatment
- 2. The number and proportion of patients with hospital admissions, operations and complications (e.g. major bleeding, sepsis or mortality) occurring within 12 months post-surgery.
- 3. New Diagnosis of cancer, either recurrent or new site within 12 months following surgery

9. Investigational Plan

9.1.1. Overall Design



* OPT at 3 and 12 months if no mucosal healing

EudraCT Number: 2007-006225-27 9.1.2. Arm 1: Standard management¹⁹:

- Pre- and post- operative chlorohexidine¹ mouthwash 0.2% use 10ml (i.e. one capful) washed around the mouth for around 1 minute and spat out, three times daily for 5 days post-operatively.
 ^{1a}In case of chlorohexidine allergy use warm salt mouthwash at 1 teaspoon per cup of warm water.
- 2. Oral antibiotics (amoxicillin² 3g oral 1 hour pre-operatively (or 1g intravenously) and 250mg tds x 5 days post-operatively

^{2a}in penicillin allergy: 600mg oral clindamycin (orally either 600mg tablet (or same dose of 75mg/5ml suspension if tablets not tolerated) 1 hour pre-operatively or intravenously 600mg at time of surgery) 1 hour pre-operatively and 200mg metronidazole (patients should be warned of interaction between alcohol and metronidazole) tds x 5 days post-operatively.

3. Minimally traumatic surgical technique

9.1.3. Arm 2: Standard management plus HBO¹

Patients will undergo 20 HBO treatments prior to surgery followed by a further 10 HBO treatments. See section 10.4. Administration of Investigational Products.

9.2. Time Schedule

Planned start date of phase III May 2010. Planned end date of phase III: February 2018.

9.3. Criteria for Patient Selection

9.3.1. Inclusion Criteria

- 1. Age > 18 years
- 2. Prior history of external beam radiotherapy (dose > 50Gy) to mandible or prior history of brachytherapy with equivalent radiation dose as above.
- 3. No evidence of cancer recurrence

Patients with previous head and neck cancer are at risk of further malignancy. Care should be taken to exclude this possibility with particular regard to:

- i. Local, regional or distant recurrence of originally treated tumour
- ii. Second primary tumour in head and neck region
- iii. Second primary tumour outside the head and neck (e.g. lung)

Careful clinical examination by a head and neck oncology specialist to exclude malignancy, blood biochemistry, head &neck / thoracic imaging and flexible nasendoscopy should be completed in keeping with local protocols and appropriate to the site and stage of the original tumour and disease free interval

- 4. Condition requiring surgery to mandible (commonest examples but not limited to: dental extraction, implant placement, surgical tooth, cyst or osteosynthesis plate removal)
- 5. Patient has read and understood information leaflet and is willing to be randomised.
- 6. Patient competent to consent and psychologically / physically fit for HBO.

9.3.2. Exclusion Criteria

1. Known contraindications to HBO

- a. Lung disease: Severe chronic obstructive airways disease; bullous lung disease, acute or chronic pulmonary infection; uncontrolled asthma, untreated pneumothorax
- b. Middle ear disease (such as previous middle ear operations, eustachian tube dysfunction or recurrent attacks of vertigo) that proves refractory to simple interventions such as grommet insertion
- 2. Prior hyperbaric oxygen therapy
- 3. Prior diagnosis of osteoradionecrosis of the mandible
- 4. Previous surgery for osteoradionecrosis
- 5. Any history of systemic bisphosphonate therapy, pentoxyphylline or tocopherol.
- 6. Pregnancy

The use of hyperbaric oxygen during pregnancy is controversial and has been carried out infrequently - in the case where pregnancy occurs, urgent advice should be sought from the trials unit.

9.3.3. Patient Screening Log

Screening will be performed upon a patient's possible eligibility for the study and must be documented on the "Patient Screening/Randomisation Log". Screening is defined as beginning with the issuing of the patient information and consent forms to the patient.

9.3.4. Patient monitoring and criteria for withdrawal from treatment

- 1. Patients will be assessed for physical and psychological fitness prior to treatment by experienced and appropriate hyperbaric medical staff.
- 2. All patients will be assessed daily for intercurrent illness prior to commencing the HBO therapy by an appropriate medical professional. Qualified appropriate attendants will be present during each HBO session.
- 3. Patients who develop intercurrent upper respiratory infections during the treatment course who are unable to equalise the pressure in the middle ear will be offered:
 - a. Decongestant therapy (pseudoephedrine hydrochloride, 60 mg, 8 hourly)
 - b. If, despite this equalisation, the patient is sufficiently impaired to preclude HBO treatment for 3 consecutive days, he/she will be offered elective myringotomy / grommet insertion or withdrawal from the study.
- 4. Where HBO sessions have been missed (from either 20 pre-op HBO sessions or 10 post-op HBO sessions), additional treatments will be added to the end of the course to compensate and patients will continue to be followed up as per protocol.
- 5. If the patient withdraws from the trial prior to treatment commencing, the patient will not be followed-up for measurement of all endpoints.

Therefore, patients may withdraw from randomised treatment for any of the following reasons:

- 1. Patient decision to discontinue treatment.
- 2. Intolerable adverse effects as judged by the investigator or the patient as described above.

If a patient is withdrawn from randomised treatment the End of Study CRF will be completed to capture date and reason(s) for treatment withdrawal. Following withdrawal from randomised treatment, patients will be treated according to local practice and will continue to be followed up as per the trial protocol unless the patient withdraws consent.

10. Investigational Products

10.1.1. Hyperbaric oxygen

The manufacturer and/ or supplier of the oxygen to be used will be dependent on standard practise within each Hyperbaric Unit.

10.2. Packaging and Labelling of Investigational Products

10.1. Investigational Medicinal Product Description

The investigational products will not be subject to any special packaging or labelling.

10.3. Preparation of Investigational Products

This will be in accordance with the standard practise at each Hyperbaric Unit.

10.4. Administration of Investigational Products

Treatment will be administered based around a version of the Royal Navy Therapeutic Table 66 - Repeat Hyperbaric Oxygen Therapy.

The patient is pressurised to 2.4 ATA at a tolerable rate. The patient is decompressed after 100% oxygen has been breathed at 2.4 ATA for a total of between 80 and 90 minutes. Air breaks while at 2.4 ATA may be introduced routinely or as required. The decompression is scheduled to control satisfactorily any risk to the patient and, if present, to the in-chamber attendant. Patients should breathe oxygen at an inspired partial pressure greater than 2.0 ATA for no more than 110 minutes during each individual treatment.

10.5 Non Investigational Medicinal Product Descriptions

Chlorohexidine Mouthwash:

An antibacterial solution inhibiting dental plaque formation and an aid in the treatment and prevention of gingivitis, maintaining oral hygiene, particularly in situations where toothbrushing is difficult to carry out. It is valuable in the management of aphtous ulceration and oral candidal infections and can be used as an adjuvant treatment for minor infections of the throat.

Is prescribed from hospital stock and will not be subject to any HOPON trial labelling.

Formulation: Clear colourless Oromucosal solution.

Packaging, storage and stability: Please refer to the SmPC.

Supplier's name: Local hospital pharmacy

Active ingredient name/dose: Chlorohexidine - Pre and post-operative chlorohexidine mouthwash 0.2% - use 10ml (i.e. one capful) washed around the mouth for around one minute and then spat out, three times daily for 5 days post-operatively.

Amoxicillin:

Amoxicillin is a moderate-spectrum, bacteriolytic, β -lactam antibiotic used to treat bacterial infections caused by susceptible microorganisms.

EudraCT Number: 2007-006225-27 Version: Is prescribed from hospital stock and will not be subject to any HOPON trial labelling.

Formulation: White to off-white granular powder filled in hard gelatine capsule shells size '2'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '250' on body.

Packaging, storage and stability: Please refer to the SmPC

Supplier's name: Local hospital pharmacy

Active ingredient name/dose: Amoxicillin - 3g oral one hour pre-operatively (or 1g intravenously) and 250mg tds x five days post-operatively.

10.6 Treatment Assignment (Randomisation)

Patients who have given informed consent and have been found to comply with all inclusion and exclusion criteria will be randomised by the randomisation centre at the Cancer Research UK Liverpool Cancer Trials Unit (LCTU).

To ensure essential entry criteria are fulfilled, randomisation can only occur following the completion and forwarding of the trial registration documents by the investigators:

- Inclusion and Exclusion Criteria
- Randomisation Form
- Consent form

The registration documents should be faxed to the LCTU. Details of the relevant fax number for randomisation are shown on the registration CRF.

Personnel from the LCTU will review the randomisation documents, confirm eligibility and record essential demographic data before allocating a unique "trial number" for each patient. The patient will then be randomised and the LCTU will contact the site by fax to confirm the treatment allocation.

Once the fax confirming randomised treatment allocation has been received by the investigator, the Investigator should add the patient's trial number and treatment allocation details to the Screening/Randomisation Log.

The subject number is to be filled in on each copy of each page on the CRF used for that patient.

10.7 Randomisation Code List

The randomisation code list will be generated by the LCTU trial statistician by means of the Stata userwritten package ralloc using block randomisation with randomly varying block length. Randomisation will be stratified by centre with allocation to treatment arms in the ratio 1:1.

Central allocation, by fax, will be undertaken by the LCTU. This will allow the patient eligibility criteria to be scrutinised and will minimise the potential for selection bias by concealing the randomisation code list from all recruiting clinicians and trial participants.

10.8 Accountability for hyperbaric oxygen treatment

The Investigator is fully responsible for the delivery of hyperbaric oxygen at each site.

10.9 Treatment Compliance

Hyperbaric oxygen will be given within the limitations previously specified in 9.3.4. The maximum treatment break between the initial 20 dives and post-operative 10 dives is 3 weeks. Patients not recommencing their HBO in the specified period will continue with their normal follow-up measurements but this protocol violation will also be recorded on the CRF.

11. Study Procedures and Assessments

Table 4. Schematic Diagram

Procedure	Following randomisa tion	At time of Surgery	3 months following surgery	6 months following surgery	12 months following surgery	End of trial (casenote review of MBS and implant survival)
Orthopantomog ram	x		Only in cases where ORN present	Х	Only in cases where ORN present	2
Clinical Photograph	X		Х	Х	Х	
Clinical Assessment	X		X	Х	Х	
Pain Assessment Chart (Appendix 7)	X		Х	X	X	
UoW QOL v4 Questionnaire (modified) (Appendix 6)	X		Х	Х	х	
Assessment of suitability for HBO	X					
Acute symptoms questionnaire (Appendix 8)		X				
Blood Sample	5	X (or at any time after randomi sation if not at the time of surgery)				
Assessment of severity of diagnosed osteoradionecro sis (where appropriate)			Х	Х	Х	Only in cases where patients have received ongoing clinical review since completing HOPON assessments

Version:9 11/01/2017

Luurae i Nuimber	. 2007-00022.)-21				VCISIOII. 7 11/01/2	2017
Assessment of				Х		Only in cases	
implants (where						where patients	
appropriate)			Х		Х	have received	
						ongoing clinical	
						review since	
						completing	
						HOPON	
						assessments	

12. Safety Reporting

12.1. Definitions:

12.1.1. Adverse Event:

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

AEs include the following:

- All suspected adverse medication reactions,
- All reactions from medication overdose, abuse, withdrawal, sensitivity, or toxicity.
- Apparently unrelated illnesses, including the worsening of a pre-existing illness.

• Injury or accidents. Note that if a medical condition is known to have caused the injury or accident, the medical condition and the accident should be reported as two separate AEs.

Abnormalities in physiological testing or physical examination findings that require clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test).

12.1.2. Serious Adverse Event (SAE)

Severity of any AE will be graded according to the World Health Organisation (WHO) toxicity criteria/National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 3, where applicable.

For each episode, the highest severity grade attained should be reported.

If an AE occurs that is not listed in the WHO/CTCAE, the Investigator will evaluate its severity using the definitions in Table 5.

Mild	Grade 1 - Does not interfere with subject's usual function			
	(awareness of symptoms or signs, but easily tolerated			
	[acceptable]).			
Moderate	Grade 2 - Interferes to some extent with subject's usual function			
	(enough discomfort to interfere with usual activity [disturbing]).			
Severe	Grade 3 - Interferes significantly with subject's usual function			
	(incapacity to work or to do usual activities [unacceptable])			
Life Threatening	Grade 4 - Results in risk of death, organ damage, or permanent			
	disability (unacceptable)			
Death	Grade 5 – Results in death (unacceptable)			

Table 5. Definition of Severity of Adverse Events

Note the distinction between the seriousness and the intensity of an AE. **Severe** is a measure of intensity; thus, a **severe** reaction is not necessarily a **serious** reaction. For example, a headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events listed below:

- results in death or is life-threatening*
- requires hospitalisation or prolongation of hospitalisation
- results in persistent or significant disability or incapacity
- results in congenital anomaly

* The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.

Serious adverse events will be followed-up until progressive disease or death.

Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately lifethreatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed above. These should also usually be considered serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation; or development of drug dependency or drug abuse.

12.1.3. Serious Adverse Reaction (SAR)

SAE suspected to have been caused by a trial drug

12.1.4. Suspected Unexpected SAR (SUSAR)

Any suspected adverse reactions related to an IMP that are both unexpected and serious.

12.2. Assessment of Adverse Events

Seriousness

This assessment is to be undertaken by the clinician responsible for the patient.

Causality (relationship to study drug)

This assessment is to be undertaken by the clinician responsible for the patient.

Definitely, probably or possibly related = adverse reaction.

Unlikely or not related = other adverse event.

Clinical assessment: Chief Investigator and the LCTU may give their own assessment but cannot override that of the clinician.

The Chief Investigator will be responsible for reviewing all SAEs.

Expectedness

Not included (or more severe than) reactions listed in the applicable product information in the Summary of Product Characteristics (SMPC, data sheet) for an authorised product.

12.3. Reporting

12.3.1. Adverse Events

AEs that occur within 28 days following the last dose of trial treatment will be recorded in the CRF and are not part of the expedited reporting procedure.

All completed AE forms must be signed off by a medically or dentally qualified member of the research team as listed on the delegation log.

12.3.2. Serious Adverse Event Reporting

Investigators **MUST REPORT ALL SERIOUS ADVERSE EVENTS (SAEs),** including disease related as well as treatment related events that occur within 28 days following the last dose of trial treatment. New diagnosis of cancer or recurrence of cancer will be reported as an SAE for the duration of the patient's involvement in the study up to 12 months follow up after surgery.

All completed SAE forms must be signed off by a medically or dentally qualified member of the research team as listed on the delegation log.

SAEs must be reported within **24 hours** of sites becoming aware of them by faxing a completed **SERIOUS ADVERSE EVENT FORM** (Appendix 4) to the LCTU, Fax: 00 44 151 794 8930/8931. Sites will receive an acknowledgement fax within two hours to confirm the SAE has been received at the LCTU. If this acknowledgement is not received, please contact the LCTU.

The Investigator must institute appropriate therapeutic action and follow-up measures in accordance with Good Medical Practice but should notify the study co-ordinator of such actions.

The minimum dataset required for a preliminary report should include the following.

Page 1

- Research subject trial number and initials.
- Date of onset of event
- Brief description of event and CTC or severity grade
- Causality relationship
- Dated signature of investigator/co-investigator and clearly printed name

Page 2

- Date of last administration of study drug.
- Causality relationship
- Dated signature of investigator/co-investigator and clearly printed name

The Chief Investigator and the LCTU will provide an annual **a Development Safety Update Report** to the UK Competent Authority and Ethical Committee.

12.3.3. Suspected Unexpected Serious Adverse Reaction (SUSAR)

The minimum data required for initial reporting is:

- The suspected Investigational Medicinal Product (IMP)
- An identifiable subject
- An adverse event assessed as serious and unexpected, and for which there is a reasonable suspected causal relationship
- An identifiable reporting source

The Chief Investigator and the LCTU will ensure that all SUSARs are reported to Competent Authorities and Ethical Committees.

- Fatal or life threatening SUSARs < 7 days after receiving the information
- All other SUSARs <15 days after receiving the information

The Chief Investigator and the LCTU will inform all investigators of SUSARs as they occur.

Expedited Reporting

- MHRA Clinical Trials Unit
- Relevant Ethics Committee.

12.3.4. Annual Reporting to MHRA and MREC

The required details will include:

- Line listing of all SARs, including SUSARs
- Aggregate table of all SARs, including SUSARs
- Summary of safety of the subjects in the trial
- Summary of published literature relevant to safety

Reference Safety Information

The reference safety information (RSI) for the IMP used in this trial is as follows:

• Medicinsk Oxygen AGA 100%, Medicinal Gas, Compressed: Section 4 of the Summary of Product Characteristics

The current version of the SmPC can be downloaded from the following website address: <u>https://lakemedelsverket.se/LMF/?q=oxygen</u>

RSI documents applicable to the trial and current reporting period are available from the HOPON Trial Coordinator.

13. Quality Assurance/Audit

Systems of quality assurance, including all elements described in this protocol have been/will be implemented within relevant institutions with responsibility for this trial. Standard Operating Procedures (SOPs) are implemented to ensure that clinical trials are conducted in compliance with regulatory requirements and Good Clinical Practice (GCP). Quality control is applied to each stage of data handling to ensure that data are accurate, reliable and processed correctly.

The HOPON trial Investigational sites, facilities, laboratories and all data (including sources) and documentation must be available for GCP audit and inspection by competent authorities or IEC. Such audits/inspections may take place at any site where trial related activity is taking place (the Sponsor's site(s), LCTU or at any investigator's site including laboratories, pharmacies etc.)

The site staff should assist in all aspects of audit/inspection and be fully cognisant of the LCTU communication strategy for multicentre trials.

13.1. Quality control

Signed CVs and GCP certificates of all clinicians and research staff will be submitted to the LCTU prior to the site opening to recruitment for the HOPON trial. This is in line with established LCTU systems and processes for ensuring the highest standard of governance for clinical trials. The Green Light Checklist in place at the LCTU means that no patients can be recruited at a particular trial site without the green light being given. It ensures that all relevant approvals, contracts/agreements and essential documents are in place before any patients are recruited to the trial.

The Trial Co-ordinator maintains a communication strategy with all centres and will signpost any centre requiring clarification in the procedure. As part of the HOPON working group, investigators attend regular Steering Committee meetings which include continuous review and discussion. Advice is available to all investigators from experts in the field at any point during the trial. All new centres recruiting patients will have the first sets of images audited, and then 10% thereafter. These will be scored as adequate / inadequate to assess the presence of ORN by an appropriate panel assembled, viewed independently by three qualified clinicians, on reviewing anonymised images. Any centres submitting photographs of inadequate standard will be offered advice and training.

13.2. Risk assessment

In accordance with the LCTU Standard Operating Procedure, a risk assessment has been completed in partnership with:

- Representatives
- Trial Sponsors
- Trial Co-ordinator
- Trial Statistician
- LCTU Operational Director

In conducting this risk assessment, the contributors consider potential patient, organisational and study hazards, the likelihood of their occurrence and resulting impact should they occur.

The outcome of the risk assessment is expressed as a percentage, assigned according to the following categories:

Score $\leq 33\%$ = Low risk Score ≥ 34 to $\leq 67\%$ = Moderate risk Score ≥ 68 to $\leq 100\%$ = High Risk

The LCTU will review recruitment rates, withdrawals and losses to follow-up, and identified problems will be reviewed by the trial working party and remedial action taken as necessary. Data submitted to the database will be centrally monitored by the LCTU to ensure that data collected are consistent with adherence to the trial protocol. Data will be checked for unusual values (range checks) and checked for consistency with participants over time. Discrepancies that have been raised can be queried, and resolved at the LCTU, or by contact with the individual site. A complete log of discrepancies and data amendments, including the date of each change and the person who changed it will be kept.

14. Confidentiality

Individual participant medical information obtained as a result of this study is considered confidential and disclosure to third parties is prohibited. Paper CRFs will be labelled with patient initials and unique trial registration number. Consent forms sent to the LCTU as part of the randomisation process may contain patient identifiers for the purpose of monitoring as described in the trial risk assessment. Such information will be stored within the patient folders in secure, locked cabinets.

15. Case Report Forms and Data Handling

15.1. Case Report Forms

LCTU will provide the investigator with duplicate NCR Case Report Forms (CRF). A separate CRF will be used for each patient enrolled and will include a carbon copy of each CRF page for the investigator to

The CRFs must be kept on file by the investigator and maintained in an up-to-date condition at all times. The investigator, or a delegated member of the research team authorised by the investigator, must sign and date all sections of CRFs used, and also any specific forms used, as indicated on the form.

Any correction(s) will be made by the investigator or designated staff on the forms before the originals are removed from the CRF, so that the corrections will appear on the investigator's copy. All such corrections must be initialled and dated by the investigator or designated staff and the reason for the correction stated unless obvious. Any corrections needed after collection of the original Forms will be by use of Data Queries. Trial sites must make a copy of any completed data query form they complete and keep these copies with the CRFs for the relevant trial patient.

Only medically qualified (sub-) investigators or delegated staff (who have been approved and signed off by the investigator on the delegation log) can sign off data on clinical assessments/safety.

15.2. Data Handling

Data recorded on the CRFs will be entered into the LCTU MACRO database.

Systematic data validation is performed by the LCTU Trial Coordinator and the Trial Statistician to obtain a clean data base prior to the statistical analysis. The HOPON Data Validation Plan will be executed following the LCTU SOPs for data management. A full data Validation Report will be produced by the Trial Coordinator and any issued resolved.

Data will be processed in accordance with the general terms and conditions of the authorisation from the 'Information Commissioner's Office' to LCTU, as required, according to national legislation implementing the Data Protection Directive; 95/46/EC.

16. Protocol Amendments

Deviations from the protocol should not occur and protocol exceptions will not be granted.

Neither the investigator(s) nor LCTU will change the Study Protocol without the written agreement between LCTU and the Chief Investigator. Any significant modification would require approval/favourable opinion by the appropriate Regulatory Authority and IEC.

Protocol Amendments become effective when written approval has been provided by the Chief Investigator, the Director of LCTU, and approval/favourable opinion from Regulatory Authorities and/or IEC has been obtained as required.

17. Agreements

17.1. Research Site Agreement

Before the initiation of the clinical trial at a site, the arrangements between LCTU and investigator/institution as laid down in the Research Site Agreement must be confirmed in writing.

Completion of Trial

17.2. Trial Completion Procedures

Investigators will be informed when patient recruitment is to cease.

Trial enrolment may be stopped at a site when the total requested number of subjects for the trial has been obtained.

The ISDMC may recommend to the TSC that the trial be stopped prematurely. Such premature termination/suspension of trial will be notified to Regulatory Authorities and IECs as required.

17.3. Archiving of Trial Documents

The investigator at each investigational site must make arrangements to store the essential trial documents, (as defined in Essential Documents for the Conduct of a Clinical Trial (ICH E6, Guideline for Good Clinical Practice)) including the Investigator Site File, until the LCTU informs the investigator that the documents are no longer to be retained.

In addition, the investigator is responsible for archiving of all relevant source documents so that the trial data can be compared against source data after completion of the trial (e.g. in case of inspection from authorities).

The investigator is required to ensure the continued storage of the documents, even if the investigator, for example, leaves the clinic/practice or retires before the end of required storage period. Delegation must be documented in writing.

The LCTU undertakes to store originally completed CRFs and separate copies of the above documents for the same period, except for source documents pertaining to the individual investigational site, which are kept by the investigator only.

At present according to ICH Guideline:

Essential documents should be retained until at least 2 years after last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the Investigational Product. These documents should be retained for a longer period however if required by applicable regulatory requirements or by an agreement with the Sponsor. It is the responsibility of the Sponsor to inform the investigator/institution as to when these documents no longer need to be retained. (ICH E6, 4.9.5)

18. Statistical Considerations

18.1. Introduction

This is a multicentre, parallel group, individually randomised superiority trial in a secondary/ tertiary referral care setting.

18.2. Blinding

The trial is open-labelled due to the different schedules of treatment administration. However, the primary outcome, the diagnosis of osteoradionecrosis at 6 months i.e. incomplete mucosal healing and presence of necrotic bone, will be assessed, via clinical photographs and radiographs by a blinded observer panel to reduce bias being introduced by knowledge of treatment allocation.

18.3. Missing Data

Missing data will be closely monitored during the trial and its occurrence will be minimised by adopting the following strategy:

(i) A general CRF completion guideline document will be provided to each site and staff will be instructed to complete the CRF in accordance with this document.

- (ii) A separate data management plan that will include instructions for checking missing data will be developed to give a detailed account of the procedures for data management.
- (iii)Data from the CRF will be entered onto a MACRO database with extensive data validation checks alerting all missing data to be queried.
- (iv)Central statistical data monitoring will summarise missing or inconsistent data periodically.
- (v) If missing data occurs consistently for particular clinicians or sites, this will be raised as a training issue.

Where missing data remain, as much information as possible will be collected about the reasons for missing data.

18.4. Sample Size

Assuming an ORN rate of 5% in the HBO arm at 6m following surgery, 103 patients per group will provide 80% power to detect a hazard ratio of 0.25 or odds ratio of 0.23 (equivalent to detecting an absolute difference of 13.5% between treatment arms) at the 5% two-sided significance level. After allowance for 6.8% drop out, 221 need to be recruited.

18.5. Patient Accrual

Recruitment is planned at 30 patients per annum until the end of the study, which in addition to 50 patients recruited from the FSC constitutes 221 in total. The total duration of the study is therefore expected to be approximately 9 years (including the feasibility study) in order to recruit the target number of patients and for all endpoints to be assessed. The trial will close after the last study follow up visit or end of study form has been completed by all patients.

18.6. Statistical Analysis Plan

The trigger for the final analysis will be when all participating patients who have received surgery have completed 12 months of post-surgery follow-up, unless the trial is terminated earlier for reasons of safety, efficacy or futility.

The trial will be analysed using Stata v13 or higher, and reported following the 'CONSORT' guidelines.

Categorical variables will be summarised as frequencies and percentages (with 95% confidence intervals), continuous variables by mean, Standard Deviation, median and interquartile range. All hypothesis tests will be undertaken using a 5% two-sided significance level.

Because the primary analysis is based on patients who actually received surgery, demographic and clinical factors for the HBO and control groups will be presented both "as randomised" and also "as receiving surgery". A multiple logistic regression analysis will be performed to confirm that these factors remain jointly uninformative for receiving surgery.

18.7.1. Patient Groups for Analysis

For this trial it will not be possible to follow the Intention to Treat (ITT) principle of "analysing as randomised" because patients do not have the intervention (HBO or standard care) until they have been randomised *and* had surgery. Some patients drop out before surgery, and this occurs more frequently in

EudraCT Number: 2007-006225-27 Version:9 11/01/2017 the HBO arm. Furthermore the clinical question to be answered is the effect of HBO among those given surgery, and not the effect of HBO in itself.

Full Analysis set: This will consist of all randomised patients who have received surgery excepting for a) patients withdrawing consent between randomisation and receiving surgery b) patients withdrawn from the study after randomisation because of irregularities with the consent process and c) patients whose information determining ineligibility existed before randomisation but was not read until after randomisation. In effect this is a "per protocol" set that may include some patients with major deviations.

Safety set: All patients who received any trial treatment.

Efficacy analyses will be performed on the full analysis set and Safety analyses will be performed on the safety set.

18.7.2. Handling of mis-randomised patients and dropouts

For efficacy analyses mis-randomised patients will be analysed as randomised, in order to follow the ITT principle. For safety analyses patients will be analysed as treated.

18.7.3. Identification and Handling of outliers

Potential outliers for continuous variables will be defined as follows: *Mild outliers*:

UQ+1.5×IQ to UQ+3×IQR

LQ - 1.5×IQ to LQ-3×IQR

Severe outliers: values more extreme than the above (Note: UQ=Upper Quartile, LQ=Lower Quartile, IQR=Inter Quartile Range)

If after transformation (chosen using a "ladder of powers" approach using the Stata command *ladder*) no outliers are apparent then no action will be taken even if values appear as outliers on the original scale, apart from use of the transformation if normality is required for a particular statistical procedure, or to remove the leverage effect of the outlying values.

Outliers that are still present on the transformed scale will be winsorised before analysis – such values will be queried but no other action taken if the result is not amended.

18.7.4. Study centre effects

Consistency of effect for the primary outcome will be assessed across the centres by a model that incorporates Centre and Treatment by Centre random effects. There will be limited capacity to investigate these formally and such centre effects are to be expected by chance.

18.7.5. Adjustment for covariates

See sensitivity analyses (below).

18.7.6. Multiplicity adjustments

No formal adjustment for multiple significance testing is to be applied.

18.7.7. Missing data

If feasible, missing baseline covariate, ORN response data and Part One (the visual analogue scale) of the pain scores will be handled by multiple imputation, performing separate multiple imputations by HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document 35

treatment arm using chained equations, as implemented in the Stata command mi impute. Plausible sets of explanatory variables will be identified in discussion with the CI. Missing Quality of life and Acute symptoms scores will not be imputed.

Once the sets of explanatory variables have been identified, separate data sets will be created for each treatment arm and 5 multiple imputations will be created for each arm, after ensuring that the primary response is included in each of the sets of explanatory variables. The multiply-imputed data sets will then be recombined for formal analysis, either using the *mim* command prefix, or if necessary a bespoke routine to estimate parameter values and combine them using Rubin's rules.

18.7.8. Sensitivity analyses

These will consist of:

1. Assessing effects of assuming:

A all presurgery dropouts would have developed ORN

B no presurgery dropouts would have developed ORN

C all presurgery dropouts would have developed ORN with risk for their arm

D all presurgery dropouts would have developed ORN with mean risk across both arms

- 2. Assessing the effect of adjustment in analysis of the primary outcome for radiotherapy dose, age, sex, cigarettes & alcohol use.
- 3. Inclusion of Multiply-imputed primary endpoint responses for all randomised patients.

4. Comparison of results using the PI's original assessment of ORN (as with the primary analysis, this will include assessment of centre effects)

5. Analysis of "blind review" ORN after including Minor Bone Spicules vs excluding cases with only Minor Bone Spicules

18.7.9. Prespecified subgroup analyses

Separate analyses will be presented for patients undergoing dental extraction, and a summary and comparison of minor bone spicule dimensions will be performed.

18.7.10. Assessment of study quality & compliance

This will be based on:

- observed and expected numbers of CRF pages separately by treatment arm and by site
- proportion of patients with major deviations by treatment arm
- proportion of patients with missing values for primary outcome, treatment arm, & covariates (as defined above)
- proportions of patients withdrawing from treatment/lost to follow-up, overall and by treatment arm

18.7.11. Definitions & Derived variables

See appendices for details of derivation of independently reviewed ORN, and details of University of Washington Quality of life (UW-QoL) presentation and analysis.

18.7.12. Description of baseline subject characteristics

Because the primary analysis is based on patients who actually received surgery, demographic and clinical factors at baseline (Age, Sex, Smoking category, Alcohol category, Radiotherapy dose and Radiotherapy duration, University of Washington Quality of life, pain scores) will be presented for the HBO and control groups both "as randomised" and also "as receiving surgery". Categorical variables will be summarised as frequencies and percentages (with 95% confidence intervals), continuous variables by mean, Standard Deviation, median and interquartile range.

A multiple logistic regression analysis will be performed to confirm that these factors remain jointly uninformative for receiving surgery (ie all p-values high).

Outcome variable	Efficacy parameter	Comment	Method
Occurrence of ORN at	Odds ratio (relative	A clinically	Exact logistic
6 months post-	to Standard Care)	significant	regression
surgery		response to	
		treatment is	
		defined as an odds	
		ratio <= 0.23	
		relative to	
		Standard Care	
Occurrence of ORN at	Odds ratio (rel <mark>at</mark> ive		Exact logistic
6 & 12 months post-	to Standard Care)	-	regression
surgery			
Severity of ORN	Odds ratio		Ordinal logistic
		-	model (if
			feasible)
Quality of life	Difference in "%		Exact logistic
	best score", and		regression
	difference in % of		
	patients choosing	-	
	the domain by time		
	point and domain		
Pain score VAS	Difference in mean		Linear regression
	score, by time point	-	with separate
			variances
Acute symptoms	Difference in AUC		Multivariate
	over 7 days (by		regression for
	item) and difference	-	item-specific
	in proportions		AUC and binary
	comfortable		"comfortable"

18.7.13. Specification and estimation of efficacy parameters

variable

18.8. Analysis of primary outcome

18.8.1. Test of efficacy

The primary test of efficacy in terms of risk of ORN at 6 months will be carried out on the Full Analysis Set using an exact logistic regression including a fixed term for treatment arm.

The null hypothesis is that inclusion of HBO treatment pre-surgery is not more effective than Standard Care alone, that is, the odds ratio is not statistically different from 1, while the alternate hypothesis is that HBO treatment is superior to Standard Care with an odds ratio of 0.23 or less. The test will be two-sided and a P-value of less than 0.05 will be declared statistically significant. Two-sided 95% confidence limits for the odds ratio will be presented for consistency with the significance test.

Significance tests for secondary endpoints will also be two-sided at 5% accompanied by 95% two-sided confidence intervals.

18.8.2. Tests of assumptions

No specific tests of assumptions for the primary endpoint are planned.

18.8.3. Analysis of secondary outcomes

The presence of ORN at 3 and 12 months will be analysed as detailed above for the primary outcome.

<u>Severity of ORN</u> cases (classified as either Notani grade I, II, III) will be tabulated using counts and percentages for each treatment group separately and treatment effect assessed using an ordinal logistic model with covariates as identified for the primary outcome, and a random effect for centre. This analysis will include patients without ORN as a notional grade 0 but exclude patients whose severity is unevaluable.

<u>University of Washington Quality of life</u> (UW-QoL) forms completed at baseline, 3, 6 and 12 months following surgery will be summarised by timepoint according to their Guidance for scoring and presentation (Derek Lowe & Simon N Rogers 2012). Scoring is scaled so that a score of 0 represents the worst possible response, and a score of 100 represents the best possible response.

A) frequency of each score by treatment arm and domain (pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder, taste, saliva, mood and anxiety) with means and standard errors. Formal comparison of treatment arms at each time point after baseline for each domain will be based on the "% best score" defined as a score of 100%

B) frequency of Health-related and Overall QoL scores over preceding 7 days (the cancer-related score will be omitted because this is compared to the month before cancer was diagnosed, and these patients are cancer-free) with means and standard errors. Formal comparison of treatment arms at each time point after baseline for each domain will again be based on the "% best score" defined as a score of at least 60.

C) frequency and percentage of patients choosing each domain as "important" by treatment arm. Formal comparison of treatment arms at each time point after baseline for each domain will use the % of patients choosing the domain.

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

<u>Pain Assessment Charts</u> completed at baseline, 3, 6 and 12 months following surgery, will be summarised by timepoint using only Part One (the visual analogue scale) in terms of mean and standard deviation by treatment arm. Formal comparison of treatment arms at each time point will compare the mean pain score between treatment arms by a linear model that allows for differences in variance, as implemented using *xtmixed* command with the option *residuals(independent,by(trt))* where trt denotes the dummy variable for treatment arm.

<u>Acute symptoms questionnaire</u> (completed for days 1-7 post-surgery). Mean scores will be tabulated by treatment arm and day for each item of Pain, Swelling, Bleeding, Difficulty in opening mouth, Difficulty in eating normal diet. For Day 8 the number (%) comfortable and able to eat normally will also be displayed. Formal comparison of treatment arms will compare the mean AUC over the 7 days for each arm and the numbers comfortable at 8 days, using a multivariate regression model that permits both binary and continuous outcomes as specified in the Stata user-written package *gllamm* (26).

<u>Outcome of MBS and Implant survival</u>. Descriptive analyses only of, respectively proportion progressing to Notani 1 or more or proportion of implants retained. If possible, actuarial methods will be used to estimate progression and survival.

18.8.4. Analysis of safety

<u>Surgery:</u> the number and proportion of patients with death, hospital admission, operations and complications (e.g. major bleeding, sepsis) occurring within 12 months post-surgery will be reported for each treatment group separately.

<u>HBO treatment:</u> adverse events related to hyperbaric insult (ege otic trauma, epistaxis) will be reported in terms of incidence and severity. This will also include events occurring within 6 months of most recent HBO treatment for patients in that arm who did not receive surgery.

<u>New Diagnosis of cancer</u>, either recurrent or new site within 12 months following surgery will be tabulated as number (%) with formal comparison between arms based on the difference in proportions.

18.9. Interim analysis and data monitoring committee

Analyses of trial data for the Independent Safety Data Monitoring Committee (ISDMC) review are initially planned at 12-monthly intervals, to assess recruitment rates and toxicity.

A single formal interim analysis will be carried out when 100 dental extraction patients have been followed up for 6 months. The Peto stopping rule will be implemented for the primary efficacy outcome (ORN rate at 6 months following surgery), and a futility analysis will also be carried out.

The Peto stopping rule (for efficacy) uses a fixed critical z value of 3 for the interim analysis, with no adjustment to the fixed sample size z value at the final analysis (Haybittle, 1971; Peto, 1976). The futility analysis will be in the form of an estimate of conditional power comparing the two treatment arms with respect to the primary endpoint.

No formal stopping rule has been adopted for futility, and the result will act purely as a guideline, to be interpreted in the light of recruitment, toxicity and results from other trials with the default intention of proceeding to the planned sample size (unless stopping early for efficacy). The target of 100 dental extraction patients corresponds to a total of approximately118 patients. All interim analyses will be

EudraCT Number: 2007-006225-27

unblinded and performed by the trial statistician. Access to the results of these analyses will be restricted to the trial statistician unless otherwise authorised by the DMC.

The formula that will be used to estimate conditional power is (Piantadosi, 2005):

$$\begin{aligned} \text{Conditional power} &= \Pr\left[z > \frac{z_{1-\alpha} - \{\sqrt{f}Z_f + \delta(1-f)\}}{\sqrt{1-f}}\right] \\ &= 1 - \Phi\left[\frac{z_{1-\alpha} - \{\sqrt{f}Z_f + \delta(1-f)\}}{\sqrt{1-f}}\right] \end{aligned}$$

Where:

• f = the fraction of the target sample size at the interim analysis. The target sample size (for which the study is powered) is 200 patients. However a check on the sample size estimate indicates that this should be 206, so we expect f will be ≈ 0.57

• $z_{1-\alpha} = 1.96$ (the standard Normal deviate corresponding to the alpha error in the sample size estimate)

- Z_f = value of the test statistic observed at the interim
- $\delta = drift parameter.$

There are three scenarios of interest:

- a) Conditional power assuming the original δ |H1 when we use the formula with $\delta = (z_{1-\alpha} + z_{1-\beta})$
- b) Conditional power assuming the current estimate of δ given by: $\delta = Z_f / \sqrt{f}$
- c) Conditional power assuming the original $\delta | H0$ for which $\delta=0$

All three estimates will be presented. However, in monitoring with the aim of possible stopping for futility, note that true futility occurs when despite possible late evidence of efficacy, the probability of a statistically significant result remains low (Moye', 2006). Hence the most "optimistic" estimate of conditional power is under scenario a) with typical thresholds for conditional power in the range 0.10 to 0.15 (Proschan et al, 2006)

Other information that may affect the decision of the DMC are:

- whether the confidence limits exclude the designed-for treatment effect
- whether the treatment effect is in the "wrong" direction: ie causing harm
- whether the above effects are robust to the planned sensitivity analyses

The trial may be terminated early by the ISDMC if there are serious concerns for patient safety. In such a case, ISDMC members will make formal recommendations to the trial working group and TSC regarding the continuation of recruitment of patients into the study and will comply with a trial-specific ISDMC charter according to ICH GCP guidelines.

Further details will be included in a separate DMC Report Plan to be signed-off before the formal interim analysis.

19. Use of information

EudraCT Number: 2007-006225-27 Version:9 11/01/2017 All unpublished information relating to this study and/or to the Investigational Product(s) is considered confidential by the LCTU.

The investigator should understand and agree that LCTU may use the information from this clinical trial in connection with the development of the product, and therefore, may disclose it as required to other investigators, to government licensing authorities, to regulatory agencies of other governments and commercial partners.

20. Publications

A draft manuscript for joint publication will be prepared and submitted in collaboration between the LCTU and the investigators, whatever the outcome of the study.

Investigators must undertake not to submit any part of their individual data for publication without the prior consent of the LCTU.

21. Contact numbers for the randomisation centre and Investigators

Surgical Units: These Units will provide screening / randomisation and surgical treatment within the HOPON trial – data recording and sample collections.

ST LUKE'S HOSPITAL:

Mr Michael Ho Consultant Maxillofacial/Head and Neck Surgeon BIHR Head and Neck Cancer Research Lead Maxillofacial Unit | Maxillofacial Unit, Horton Wing, St. Luke's Hospital, BD5 ORN Bradford Teaching Hospitals NHS Foundation Trust

LEEDS:

Mr Peter Nixon, Locum Consultant in Restorative Dentistry Leeds Dental Institute & Leeds Institute of Oncology Leeds Teaching Hospitals NHS trust Level 6 Clarendon Way Leeds LS2 9LU

MUSGROVE PARK HOSPITAL:

Mr Manuel Blanco-Guzman Consultant Oral & Maxillofacial Surgeons Maxillofacial Unit Musgrove Park Hospital Taunton and Somerset NHS Trust Taunton TA1 5DA

ABERDEEN ROYAL INFIRMARY:

Dr Ruth Stephenson Consultant in Anaesthesia and Hyperbaric Medicine Hyperbaric Unit Aberdeen Royal Infirmary

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

QUEEN ALEXANDRA HOSPITAL:

Professor Peter Brennan Consultant Oral & Maxillofacial Surgeon & Professor of Surgery Department of Oral & Maxillofacial Surgery Portsmouth Hospitals NHS Trust Queen Alexandra Hospital Cosham Portsmouth PO6 3LY

ST RICHARD'S HOSPITAL:

Peyman Alam Consultant Oral & Maxillofacial Surgeon Clinical Lead for Head & Neck Surgical Oncology Clinical Lead for Thyroid/ Parathyroid Surgery St Richard's Hospital Chicheser West Sussex PO19 4SE

WORTHING GENERAL HOSPITAL:

Peyman Alam Consultant Oral & Maxillofacial Surgeon Clinical Lead for Head & Neck Surgical Oncology Clinical Lead for Thyroid/ Parathyroid Surgery St Richard's Hospital Chicheser West Sussex PO19 4SE

UNIVERSITY HOSPITAL AINTREE:

Professor Richard Shaw Professor of Head & Neck Surgery Honorary Consultant in Oral & Maxillofacial Surgery &Mr Christopher Butterworth Consultant in Restorative Dentistry University Hospital Aintree NHS Foundation Trust Lower Lane Liverpool L9 7AL

LIVERPOOL UNIVERSITY DENTAL HOSPITAL

Mr Christopher Butterworth Consultant in Restorative Dentistry The School of Dental Sciences Pembroke Place

UNIVERSITY HOSPITAL BIRMINGHAM Mr Prav Praveen

Consultant Maxillofacial Surgeon University Hospital Birmingham NHS Foundation Trust Dept Maxillofacial Surgery Edgbaston Birmingham B15 2TH

ST BARTHOLOMEW'S HOPSITAL

Professor Iain Hutchison Consultant in Oral and Maxillofacial Surgery West Smithfield London EC1A 7BE

ROYAL DEVON AND EXTER HOSPITAL

Mr John Bowden Consultant Oral and Maxillofacial Surgeon Department of Oral and Maxillofacial Surgery Barrack Road Exeter Devon EX2 5DW

NORTH DEVON DISTRICT HOSPITAL

Mr John Bowden Consultant Oral and Maxillofacial Surgeon Exeter and North Devon Combined Maxillofacial Unit Raleigh Park Barnstaple Devon EX31 4JB

YEOVIL DISTRICT HOSPITAL

Mr Manuel Blanco-Guzman Consultant Oral & Maxillofacial Surgeon Higher Kingston Yeovil, Somerset BA21 4AT

GUY'S HOSPITAL

Mr Andrew Lyons Consultant Oral & Maxillofacial Surgeon 10th Floor, Tower Wing St. Thomas Street London SE1 9RT

UNIVERSITY HOSPITAL BRISTOL

Dr Matt Beasley Consultant Clinical Oncologist Bristol Haematology and Oncology Centre Level 0 Horfield Road Bristol BS2 8ED

NORTHWICK PARK HOSPITAL

Mr Bhavin Visavadia Consultant Oral & Maxillofacial Surgeon Maxillofacial Unit Watford Road Harrow Greater London HA1 3UJ

UNIVERSITY COLLEGE HOSPITAL

Mr Colin Liew Consultant Head and Neck/Maxillofacial Surgery Head & Neck Centre 1st Floor East Wing 250 Euston Road London NW1 2PG

Hyperbaric Units: These Units will provide hyperbaric oxygen therapy to participants referred by recruiting centres / assess each participant referred to this unit for fitness for pressure exposures prior to hyperbaric oxygen therapy.

WIRRAL

Dr Tristan Cope MBChB FRCA FFICM Medical Director North West Emergency Recompression Unit Spire Murrayfield Hospital Holmwood Drive Thingwall Wirral CH61 1AU

ABERDEEN

As Above

HULL

Dr G Purdy, North of England Medical Hyperbaric Unit, BUPA Hospital Lowfield Road, Anlaby, Hull HU10 7AZ

PLYMOUTH

EudraCT Number: 2007-006225-27 Version: 9 11/01/2017 Dr Christine Cridge, Medical Director, The Hyperbaric Medical Centre, Tamar Science Park, Research Way, Derriford, Plymouth, Devon. PL6 8BU

LONDON

Dr Pieter Bothma, Medical Director London Hyperbaric Medicine and Wound healing Centre, Leytonstone, London, E11 1RG

PORTSMOUTH

Dr Mark Glover, Medical Director, Hyperbaric Medicine Unit, St Richard's Hospital, Spitalfield Lane, Chichester, West Sussex, PO19 6SE

CARDIFF

Dr Christine Cridge, Medical Director, South Wales Hyperbaric Centre (DDRC), Spire Cardiff Hospital, Croescadarn Road, Pentwyn, Cardiff, CF23 8XL.

22. REFERENCES

1. Marx RE, Johnson RP, Kline SN (1985) Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin 111(1):49-54

2. Notani K, Yamazaki Y, Kitada H, Sakakibara N, Fukuda H, Omori K, Nakamura M (2003) Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy 25:181-186

3. Clayman L (1997) Management of dental extractions in irradiated jaws: A protocol without hyperbaric oxygen therapy 55:275-281

4. Kanatas AN, Rogers SN, Martin MV (2002) A survey of antibiotic prescribing by maxillofacial consultants for dental extractions following radiotherapy to the oral cavity 192(3):157-60

5. Vudiniabola S, Pirone C, Williamson J, Goss AN (1999) Hyperbaric oxygen in the prevention of osteoradionecrosis of the jaws 44(4):243-7

6. Lambert P, Intriere N, Eichstaedt r (1997) Management of dental extractions in irradiated jaws: A protocol with hyperbaric oxygen therapy 55:268-74

7. Tong A, Leung A, Cheung J, Sham J (1999) Incidence of complicated healing and osteoradionecrosis following tooth extraction in patients receiving radiotherapy for treatment of nasopharyngeal carcinoma 44(3):187-94

8. Giebfried JW, Lawson W, Biller HF (1986) Complications of hyperbaric oxygen in the treatment of head and neck disease 94:508-12

9. Feldmeier (Editor) (2003) Hyperbaric oxygen 2003: indications and results – hyperbaric oxygen therapy committee report. Undersea and Hyperbaric Medical Society, Undersea and Hyperbaric Medical Society, Dunkirk, MD (2003) chapter 15

10. Sulaiman F, Huryov JM, Zlotolow IM (2003) Dental extractions in the irradiated head and neck patient: a retrospective analysis of memorial sloan–kettering cancer center protocols, criteria and end results 61(10)1123-31

11. Wahl M (2006) Osteoradionecrosis prevention myths64(3):661-9

12. Kanatas A, Lowe D, Harrison J, Rogers SN (2005) Survey of the use of hyperbaric oxygen by maxillofacial oncologists in the UK 43(3):219-25

13. Rogers SN, Magennis P (2007) Survey of the fellows regarding a national study into treatment with hyperbaric oxygen 45(5):433-5

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

14. Shaw RJ, Sutton AF, Cawood JI, Howell RA, Lowe D, Brown JS, Rogers SN, Vaughan ED (2005) Oral rehabilitation after treatment for head and neck malignancy 27(6):459-70

15. Granström G, Tjellström A, Branemark PI (1999) Osseointegrated implants in irradiated bone: A case-controlled study using adjunctive hyperbaric oxygen therapy 57(5):493-9

16. Granström G (2005) Osseointegration in irradiated Cancer Patients: An Analysis With Respect to Implant Failures 63(5):579-85

17. Annane D, Depondt J, Aubert P, Villart M, Géhanno P, Gajdos P, Chevret S (2004) Hyperbaric Oxygen Therapy for Radionecrosis of the jaw: A Randomised, Placebo-Controlled, Double-Blind Trial from the ORN96 Study Group 22(24):4893-900

18. Rogers SN (2005) Does the Annane paper (2004) signal the end of HBO for ORN? 43(6):538-9

19. Kanatas AN, Rogers SN, Martin MV (2002) A Practical Guide for Patients undergoing Exodontia following Radiotherapy to the Oral Cavity 29(10):498-503

20. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part I: Introduction and design. British Journal of Cancer 1976; 34:585-612)

21. Derek Lowe & Simon N Rogers (2012) Guidance for scoring and presentation. Forms completed at baseline, 3, 6 and 12 months following surgery.

22. Haybittle J (1971) "Repeated assessment of results in clinical trials of cancer treatment" Brit J Radiology 44: 793-797

23. Moye' LA (2006) "Statistical Monitoring of Clinical Trials. Fundamentals for Investigators" New York; Springer

24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. (1976) "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design". Br J Cancer. 34(6): 585–612

25. Piantadosi S. (2005) "Clinical Trials. A methodologic perspective" Hoboken NJ; John Wiley

26. Proschan MA, Gordon Lan KK, Wittes JT (2006) "Statistical Monitoring of Clinical Trials. A unified approach" New York; Springer

27. Rabe-Hesketh, S., Pickles, A. and Skrondal, S. (2004) GLLAMM Manual. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 160).

<To be printed on Trust headed paper>

PATIENT CONSENT FORM (please read carefully)

HOPON: Hyperbaric Oxygen to Prevent Osteoradionecrosis

Name of Researcher:___

- 1. I confirm that I have read and understand the information sheet dated (version) describing the above study and have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.
- 2. I understand that my participation in this study is voluntary and that I am free to withdraw at any time without giving a reason, without my medical care or legal rights being affected.
- 3. I understand that sections of my medical notes and data collected during the study may be looked at by responsible individuals involved in this research or from regulatory authorities where it is relevant to my taking part in research. I give permission for these individuals to have access to my records.
- 4. a) I give permission for a sample of my blood to be taken and stored for research into the effects of radiotherapy. (If you do not wish to give this permission, do not initial the box you can still participate in the trial).
- 4. b) I give permission for DNA to be extracted from the blood for current and future genetic research into the effects of radiotherapy.
- 5. I give permission for a copy of my consent form to be sent to the Liverpool Clinical Trials Unit (where it will be kept in a secure location), to allow confirmation that my consent was given.
- 6. I agree to allow my General Practitioner and any other relevant medical practitioner to be informed of my involvement in the study.
- 7. I agree to take part in the above study.
- 8. I agree that data from the study can be sent outside the EU.

Name of Patient	Date	Signature	
Name of person taking consent (if different from researcher)	Date	Signature	
Researcher	Date	Signature	

Please initial







.

Three copies required: one for patient, one for researcher and one for hospital case notes.

<To be printed on Trust headed paper>

PATIENT INFORMATION SHEET

HOPON: Hyperbaric Oxygen to Prevent Osteoradionecrosis

You have been invited to take part in a research study. Before you decide it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and talk to others if you wish.

- Part One tells you the purpose of the study and what will happen to you if you take part.
- Part Two gives you more detailed information about the conduct of the study.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

Part 1

What is the purpose of the trial?

This study has been designed to find out whether the use of oxygen treatment may help your jaw heal after minor surgery. Healing problems can occur more often after radiotherapy.

We will take precautions to reduce the effects of surgery, but even so there is a small risk of healing difficulties. Having the extra oxygen treatment might prevent this although at the moment nobody knows this for certain.

This trial is to find whether there is any difference between two different types of treatment. If you agree to take part, you will be randomly allocated to one of two groups:

- 1) Surgery with antiseptic mouthwash and antibiotics.
- 2) Surgery with antiseptic mouthwash and antibiotics, also with oxygen treatment.

This means that half of all patients will be given oxygen treatment. Therefore whether you are allocated to be treated with oxygen will be decided by chance. Whichever group you are allocated you will be monitored closely.

Why have I been chosen?

You have previously received radiotherapy and now require minor jaw surgery. This may be to treat a dental problem, to place implants or simply the removal of teeth. After this surgery, difficulties with healing can occur and doctors use the term "osteoradionecrosis" of the jaw in these cases.

Do I have to take part?

No. It is up to you to decide whether or not to take part. If you do you will be asked to sign a consent form. You are free to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision not take part, will not affect the standard of care you receive.

Attendances, travelling additional costs

Involvement in the HOPON trial will require appointments at three and six months after jaw surgery. For those patients receiving oxygen treatment, daily visits to the oxygen treatment centre will be arranged. It may be possible for the health service to help with transport if needed, but these arrangements will vary in different trial centres. Please discuss transport arrangements if you feel this may be a problem.

What will happen to me during the trial?

For the patients receiving the oxygen treatment, they will receive it at a dedicated clinic. The oxygen treatment lasts about one and a half hours per day and is given as an outpatient, or in other words, you will be free to go home after this. The oxygen treatment consists of 20 treatments prior to surgery and 10 afterwards.

For the patients treated without oxygen, the surgery is carried out after giving antibiotics in the usual way.

For either group, whether surgery is done under local or general anaesthetic will be decided on by your surgeon or dentist in the usual way.

After you have been treated you will be required to attend hospital for a follow-up visit at 3,6 and 12 months. During these visits you will have an examination. Jaw x-rays and clinical photographs will also be taken.

One aspect of this study involves assessing how any treatment you receive affects the quality of your life and post-operative recovery. Our research nurses will ask you to fill in a questionnaire that asks these questions. The questionnaire will be completed when you consent to enter the study and attend for your treatment or follow-up appointments. It is very important for you to answer all the questions in the questionnaires for us to accurately assess the impact of the disease and treatment upon you.

Blood samples

Radiotherapy may lead to damage to tissues in and around the jaws. In order to further understand these changes we wish to collect and store a blood sample at the time of your minor surgery. These would be stored and used for scientific research but would not help with your care.

What are the alternatives for treatment?

If you decide not to participate in the study, then your doctor will discuss other options with you.

Are there any side-effects associated with these treatments?

Hyperbaric Oxygen Treatment:

Oxygen treatment in a high-pressure chamber has a proven safety record and many patients are routinely treated in this way. There are some medical conditions that prevent us recommending oxygen treatment therefore we will ask you particularly about some lung and ear disorders which may be relevant.

People having repeated treatments with high-pressure oxygen therapy sometimes notice a feeling of tiredness. This effect is apparent later in the day after a treatment in the morning and disappears by the following day. It is rarely, if ever, enough to interfere with normal daily activities. Some people notice temporary changes in their vision over the course of many treatments. This may cause a mild degree of short-sightedness, which may improve or worsen vision, depending on any pre-existing short- or long-sightedness. If this does occur, you can expect it to have returned fully to normal within twelve weeks of

HOPON Protocol. A Confidential CR-UK Liverpool Cancer Trial Unit Document

EudraCT Number: 2007-006225-27 Version:9 11/01/2017 finishing treatment. Tiredness and temporary mild visual changes are common but will always resolve after these oxygen treatments.

The changes in pressure can cause damage to the middle ear or sinus if the pressures in them are not equalised. This may cause problems such as pain and/or a ruptured eardrum but is not common, occurring around one in fifty patients (2%). This can be prevented easily by notifying the attendant that you have a problem and the compression or decompression can be stopped immediately. These problems can often be anticipated and simple procedures may be used, such as drainage tubes in the ears, to prevent them if necessary.

The high-pressure chamber is a relatively confined space and it occasionally induces feelings of claustrophobia. About one person in fifty may be affected (2%). If you are, please remember that you are in control at all times and that you can leave the chamber at any time.

A very rare side effect of breathing oxygen at the pressure used is having a fit (seizure) and this occurs less than one in ten thousand patients (0.01%). This is short-lived and easily dealt with and there are no lasting effects. You may not be eligible to take part if you have had any seizures in the past, as this may predispose you to having an oxygen seizure. If there are abnormalities in the lung, or the person holds her breath, it is possible for gas bubbles to enter the blood and to cause problems. These complications are extremely unlikely with the slow pressure changes used in this study and can be totally avoided by carefully screening patients for lung problems, and by breathing normally at all times.

Antibiotic Treatment:

Antibiotics of all types occasionally cause allergy or upset stomach. The antibiotics used in this study are in routine use.

What are the possible benefits of taking part?

We hope that the treatments will help you. However, this cannot be guaranteed. The information we get from this study may help us to improve the future treatment of patients who have had radiotherapy to their jaws.

What are the possible disadvantages and risks of taking part?

As part of the study you will undergo at least two jaw x-rays. The dose of radiation you will receive could be equivalent to around one week of natural background radiation. The National Radiological Protection Board described this natural background radiation as 'Low Risk'. However, you would receive the same dose from the x-rays in this trial as those required by routine care in the NHS (UK) so you are not exposed to very much additional radiation by taking part in this trial.

What if there is a problem?

Any complaint about the way you have been dealt with during the study or any possible harm you might suffer will be addressed. The detailed information on this is given in Part 2.

Will my taking part in this study be kept confidential?

Yes. All information which is collected about you during the course of this research will be kept strictly confidential. With your permission we will inform your GP of your participation in the study. Other than this, any information about you that leaves the hospital will have your name and address removed so you cannot be identified from it. A copy of your signed consent form will be sent to the Liverpool Cancer Trials Unit (where it will be kept in a secure location), to allow confirmation that your consent was given.

EudraCT Number: 2007-006225-27 Contact for Further Information

Should you have any further queries regarding this study or about any of the treatments described above:

Please feel free to ask your doctors any questions about the study or about any of the treatments described above.

Please contact___

Name and Title

On_

This completes Part 1 of the Information Sheet.

If the information in Part 1 has interested you and you are considering participation, please continue to read the additional information in Part 2 before making any decision.

Part 2

What if new information becomes available?

Sometimes during the course of a research project, new information becomes available about the treatment/drug that is being studied. If this happens, your research doctor will tell you about it and discuss with you whether you want to continue in the study. If you decide to withdraw your research doctor will make arrangements for your care to continue. If you decide to continue in the study you will be asked to sign an updated consent form.

Also, on receiving new information your research doctor might consider it to be in your best interests to withdraw you from the study. He/she will explain the reasons and arrange for your care to continue.

If the study is stopped for any other reason you will be told why and your continuing care will be arranged.

What will happen if I don't want to carry on with the study?

If you do not wish to continue attending hospital, we would be grateful if you would allow us keep in touch with your General Practitioner and Dentist to let us know your progress. If you withdraw, information collected may still be used if you allow. Any stored blood samples that can still be identified as yours will be destroyed if you wish.

What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak with the researchers who will do their best to answer your questions. If you remain unhappy and wish to complain formally, you can do this trough the NHS Complaints Procedure. Details can be obtained from the hospital.

If you are harmed by taking part in this research project, there are no special compensation arrangements. If you are harmed and this is due to someone's negligence, then you may have grounds for a legal action for compensation against the NHS trust where you are being treated but you may have to pay for your legal costs. The normal National Health Service complaints mechanisms should be available to you (if appropriate).

In the event of defective product then you may have grounds for a legal action for compensation against the manufacturer, but you may have to pay for your legal costs.

Will my taking part in this study be kept confidential?

If you join the study, some parts of your medical records and the data collected for the study will be looked at by authorised persons from Cancer Research UK or their collaborators who also involved in organising this research project. They may also be looked at by representatives of regulatory authorities and by authorised people from the Trust or other NHS bodies to check that the study is being carried out correctly. All will have a duty of confidentiality to you as a research participant and nothing that could reveal your identity will be disclosed outside the research site.

Data collected during the study may be transferred for the purpose of analysis/registration within or outside the European Union. Some countries outside Europe may not have laws which protect your privacy to the same extent as the Data Protection Act in the UK or European Law. We will take all reasonable steps to protect your privacy.

Involvement of the general practitioner/ family doctor (GP)

With your consent, your GP will be informed of your involvement in the trial. Any other medical practitioners who treat you, e.g. should you be admitted to hospital for any reason, will also be informed.

What will happen to any samples I give?

With your permission, we would like to transfer a blood sample we take from you to the University of Liverpool and store it there. The researchers at the University of Liverpool work closely with other scientists and, with your permission, your samples may be transferred to these research collaborators for use in future scientific studies. These samples will be used only for investigating the effect of your genetic (DNA) information on the severity of radiation damage and will not be used for any commercial purposes.

The samples will be kept in a secure place until we need them; nobody outside of the study will have access to **any** confidential information that you give to us. Confidential details (such as your name, address and GP details) will be kept locally and not made available to collaborators.

Your sample will be coded and the researchers carrying out tests on the samples will not be given information they do not need to carry out the tests and analyse the results. Coded is not the same as anonymous. It will be possible to use the codes to identify that a result is from your sample. However, we do not plan to do this unless there is a good research reason to do so. We will maintain this information so that we can properly manage the samples donated. For instance, sometimes we may need to update our record of your clinical details to help us interpret the results of tests.

Will any genetic tests be done?

There are some known genes that alter the body's response to radiotherapy and we may try to carry out research into these genes on your samples.

What will happen to the results of the research study?

It is intended that once the study is complete a report will be written and the results will be published to make them available to the public and medical community. You will not be named or identified in any publication.

Who is organising and funding this research?

This research project is funded by Cancer Research UK; they are supporting this study by providing funding for staff to co-ordinate this trial. It is being sponsored by the University Hospital Aintree NHS Foundation Trust and the University of Liverpool.

Your doctor will not receive any payment for including you in this study.

Who has reviewed the study?

The study has been reviewed for scientific content by members of the Cancer Research UK peer review committee and a Multi-Centre Research Ethics Committee has reviewed the study for ethical considerations. The trial has the support of the National Cancer Research Institute.

Thank you for taking the time to read and consider this information sheet. Should you decide to take part in the study, you will be given a copy of the information sheet and a signed consent form to keep.

Version 3—17/06/10 Serious Adv	erse Event Form (Page	1) Page 1 of 2
H O P O N Project	Trial Number	Patient Initials
All follow up information MUST be added t Date initial report sent to Liverpool Cancer Tr	o THIS form	da/mm/yyyy
Patient's Treatment Arm		te of last HBO treatment:
Date and time of	Date and time of hr Clock offset (if resolved)	dd/mm/yyyy 24 hr Clock
Outcome Resolved Improved Unchanged	Worse Date/time of death (if applicable) Death Unknown	dd/mm/yyyy 24 hr Clock
Adverse Event:		Severity*
Description (signs and symptoms) and diagn	osis (if applicable)	1 = Mild 2 = Moderate 3 = Severe
Overall Diagnosis:		
Relevant test results/lab data		
CHANGE IN HBO		DEFINITION OF "SERIOUS"
HBO Withdrawn	Yes No	CHECK ALL APPROPRIATE
HBO reduced	Yes No	Subject died
If withdrawn/reduced, did symptoms resolve?		Hospitalisation
Did event reappear if HBO reintroduced? CAUSALITY:	Yes No	Involved permanent or significant disability or
In your opinion was Definitely Probably the adverse event Related Related related to:	Possibly Probably Unrelated Related Unrelated	incapacity Life threatening
HBO Treatment		Congenital anomaly
condition/ other illness		
Investigator Signature		
Investigator Name	Date	dd mm yyyy

Only medically qualified delegated clinicians (who have been approved and signed off by the Principal Investigator on the delegation log) can sign off data on the SAE form.

Version 3—17/06/10	Seriou	ıs Adver	se Event Fo	rm (Page 2)	Page 2 of 2	
H O P	O N					
Project	<u> </u>		Trial Number		Patient Initials	
All follow up informa	ation MUST I	be added to T	HIS form			
Trial medication and	concurrent	drug informa	tion			
Drug	Route	Daily Dose/ Units (of infusion rate if IV)	Date/time started dd/mm/yyyy hh:mm	Date/time stopped dd/mm/yyyy hh:mm	Is drug sus- Disease pected of indication causing SAE Y N	
1					ЦЦ	
2		·			0	
3						
4						
5						
6						
7						
88						
9						
10					0	
11						
12						
13						
14						
15						
16					 	
17					00	
18						
Investigator signature					dd mm yyyy	
Please fax complete	d form to the					
SIGNED:		PRI	NT NAME:	DATE	:/	

Only medically qualified delegated clinicians (who have been approved and signed off by the Principal Investigator on the delegation log) can sign off data on the SAE form.

INSERT SITE HEADER

GP Name GP Address 1 GP Address 2 GP Address 3 GP Post Code

Dear Dr.

RE: HOPON - A Randomised Control Trial of Hyperbaric Oxygen (HBO) to prevent Osteoradionecrosis of the Irradiated Mandible.

Patient Name:....

Date of Birth:

NHS Number:.....

After giving written informed consent, the above patient has been entered into a clinical trial which aims to investigate the benefit of HBO in the prevention of osteoradionecrosis (ORN) at the time of a surgical procedure to the "at risk" irradiated mandible.

Your patient has been randomised to receive:

- 1) Arm 1*: Standard management : i.e.: pre- and post- operative chlorohexidine mouthwash, antibiotics, minimally traumatic surgical technique
- 2) Arm 2*: Standard management plus HBO: Patients will undergo 20 HBO treatments prior to surgery followed by a further 10 daily HBO treatments.

* Delete as appropriate.

Hyperbaric Oxygen treatment is occasionally associated with side effects such as decompression illness, oxygen toxicity, barotraumas and claustrophobia.

If your patient has been randomised to receive HBO (arm 2), they will be required to attend the specified Hyperbaric Unit in your area for a total of 30 treatments as part of the trial.

If you require further details please contact.....


Yours sincerely,

EudraCT Number: 2007-006225-27 **APPENDIX 5. HOPON Registration/ Randomisation form**

Vertion	5	29/04/2010

dd mm yyyy Consultant: Unit telephone no:	
Unit telephone no: Unit fax no: Randomising Clinician (if different from consultant): Patient Initials: Date of Birth: dd_mmyyyy Screening Number: (Taken from Screening Log)	
Randomising Clinician (if different from consultant): Patient Initials: Date of Birth:// Gd mm _yyyy Screening Number: (Taken from Screening Log)	
Patient Initials: Date of Birth://dd mm_yyyy Screening Number: (Taken from Screening Log)	
Screening Number: (Taken from Screening Log)	
Eligibility Criteria	
1. Age > 18 years	
Prior history of external beam radiotherapy (dose > 50Gy) to mandible or prior history of brachytherapy with equivalent radiation dose as above.	
 No evidence of cancer recurrence Patients with previous head and neck cancer are at risk of further malignancy. Care should be taken to exclude this possibility with particular regard to: i) Local, regional or distant recurrence of originally treated tumour 	
II) Second primary tumour in head and neck region III) Second primary tumour outside the head and neck (e.g. lung). Careful clinical examination by a head and neck oncology specialist to exclude malignancy, blood biochemistry, head &neck / thoracic imaging and flexible nasendoscopy should be com in keeping with local protocols and appropriate to the site and stage of the original tumour an disease free interval.	d
 New diagnosis of condition requiring surgery to mandible (commonest examples but not limited to: dental extraction, implant placement, surgical tooth, cyst or osteosynthesis plate removal) 	
Patient has read and understood information leaflet and is willing to be randomised.	
Patient competent to consent and psychologically / physically fit for HBO.	
No known contraindications to HBO (see inside front cover of CRF booklet)	
 No prior hyperbaric oxygen therapy No prior diagnosis of esteorogic permises of the mandible 	8
 No prior diagnosis of osteoradionecrosis of the mandible No history of systemic bisphosphonate therapy, pentoxyphylline or tocopherol. 	
11. Not pregnant	
Which hyperbaric chamber unit will the patient be referred to if they are randomised to the To randomise, please telephone the CR-UK Liverpool Cancer Trials Unit (0151 79 give notice, then fax this form along with a copy of the patient's signed Written In Consent form to Fax: 0151 794 8930.	4 8934) to
INVESTIGATOR'S NAME:	/ gation log) has signed the HOPON trial.
TRIALS OFFICE USE ONLY	
Reference Representation Standard Treatment	/

ŀ	1	ο	Р	ο	Ν												
			Project						Tri	al Num	ber		-		Pa	tient Ini	tials
le	stior	ns by		one b	bout yo iox for e				lity of li mm/yyyy		the p	ast sev	en day	s . Ple	ase an	swer al	l of the
	Pair	n . (T	ick one	box)													
		Ther I hav I hav	e mode e seve	d pain erate p re pair	not ne pain - re n contro n, not co	quires lled on	regula ly by p	r meo	ription I			amol). morphi	ne).				
2.	App	beara	nce. (Tick o	ne box)												
		The My a I feel	change ppeara signifi	in my ince b cantly	e in my appea others r disfigur eople d	rance i ne but ed and	s mino I rema I limit n	r. in ac ny ac	tivities	due to	my apr	pearanc	e.				
8.	Acti	ivity.	(Tick	one bo	ox)												
		Ther I am I don	e are ti often t 't go ou	mes w red ar ut beca	l have e hen I c id have ause I c d or cha	an't kee slowee lon't ha	ep up r d down ve the	my a strer	activitie ngth.			till get o	out.				
1.	Rec	reati	on. (T	ick on	e box)												
		Ther Ther Ther	e are a e are n e are s	few th nany ti evere		an't do nen I wi ons to v	but I s sh I co	still g uld g	et out a jet out	and enj more, k	oy life. out l'm	not up t	o it. I watch	TV.			
5.	Swa	allow	ing. (1	Tick or	ie box)												
		l can I can	not sw only s	allow o wallow	vell as o certain s liquid because	solid fo <mark>fo</mark> od.		n the	e wrong) way'' a	and cho	okes me	9.				
ð.	Che	ewing	. (Ticł	k one k	oox)												
		l can	eat so	ft solic	l as eve ls but c w soft s	annot d	hew so	ome	foods.								
	Spee	ech.	(Tick o	ne box	<)												
		I hav Only	e diffic	ulty sa nily an	d friend	me wo	rds but			ndersto	od ovei	the ph	one.				



- □ Saliva
- Saliva
 Activity
- □ Speech
- □ Mood
- Recreation
- □ Shoulder
- □ Anxiety

FOR SITE STAFF ONLY: SIGNED:

PRINT NAME:

DATE: __/__/

Project Trial Number Patient Initi 14. In general, would you say your health-related quality of life during the past 7 days has been: (Tick one box) Outstanding Outstanding Outstanding Outstanding Very good Pair Poor 15. Overall quality of life includes not only physical and mental health, but also many other factors, such as fa fair (Properties) in valice activities that are important to your enjoyment of life. Considering rything in your life that contributes to your personal well-being, rate your overall quality of life during the past days (Tick one box) Outstanding Outstanding Very good Outstanding In ave no problems in walking about I have no problems in walking about I have no problems with self-care I have no problems washing of dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).	н	ΟΡ	O N				
box) Outstanding Very good Good Fair Poor Very poor Very poor 15. Overall quality of life includes not only physical and mental health, but also many other factors, such as faity, friends, spirituality, or personal leisure activities that are important to your enjoyment of life Considering; nything in your life that contributes to your personal well-being, rate your overall quality of life during the part days. (Tick one box) Outstanding Outstanding Very good Good Fair Poor Poor Very good Good Good Fair Poor Very poor Very poor 16. Mobility. (Tick one box) I have some problems in walking about I am confined to bed 17. Self Care. (Tick one box) I have no problems washing or dressing myself 1 am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).		Project	: :		Trial Number		Patient Initials
Very good Good Fair Coord Good Fair Four Coord Coord Fair Four Coord Coord Fair Coord Coord Fair Coord Coord Fair Coord Coord Fair Foor Coord Foor Coord Foor Foor Coord Foor Foor Coord Foor Foor Foor Foor Foor Foor Foor		general, woul	ld you say your	health-related q	uality of life during	<u>the past 7 days</u>	has been: (Tick one
 IV, friends, spirituality, or personal leisure activities that are important to your enjoyment of life. Considering rything in your life that contributes to your personal well-being, rate your overall quality of life during the part days. (Tick one box) Outstanding Very good Good Fair Poor Very poor 16. Mobility. (Tick one box) I have no problems in walking about I have some problems in walking about I am confined to bed 17. Self Care. (Tick one box) I have no problems with self-care I have some problems with self-care I have some problems with self-care 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed). 		Very good Good Fair Poor	9				
 Very good Good Fair Poor Very poor 16. Mobility. (Tick one box) I have no problems in walking about I have some problems in walking about I am confined to bed 17. Self Care. (Tick one box) I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).	ily, friei rything	nds, spirituali in your life th	ty, or personal le nat contributes te	eisure activities t	hat are important to	your enjoyment	of life. Considering ev
 I have no problems in walking about I have some problems in walking about I am confined to bed 17. Self Care. (Tick one box) I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).		Very good Good Fair Poor	3				
 I have some problems in walking about I am confined to bed 17. Self Care. (Tick one box) I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).	16.	Mobility. (Tick one box)				
 I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed).		I have some	e problems in wa				
 I have some problems washing or dressing myself I am unable to wash or dress myself 18. Please describe any other issues (medical or nonmedical) that are important to your quality of life have not been adequately addressed by our questions (you may attach additional sheets if needed). 	17.	Self Care.	(Tick one box)				
have not been adequately addressed by our questions (you may attach additional sheets if needed).		I have some	e problems wasl	hing or dressing	myself		
	···· ··· ···						
							•• ••• ••• ••• ••• •••

APPENDIX 7. Pain Assessment Questionnaire

Project Part One Please describe the pain you hav part of the chart that best matches Least Possible Pain Part Two Use of painkillers		Patient Initials over the last 24 hours – please cross the
Please describe the pain you have part of the chart that best matches Least Possible Pain Part Two		
part of the chart that best matches Least Possible Pain Part Two		
Pain Part Two		Warst Descible
Part Two		
		' Pain
Use of painkillers		
Which painkillers have you used	over the last 24 hours?	
None	Listed as follows	
Painkiller 1		
Name		
Dose	Please state units	
How often used?		
Occasionally	Once daily	Twice daily
Three times daily	Four times daily	Other
		If Other, specify
Painkiller 2		
Name	Please state units	
Dose	····	
How often used?		
Occasionally	Once daily	Twice daily
Three times daily	Four times daily	Other
		If Other, specify
Painkiller 3		
Name		
Dose	Please state units	
How often used?		
Occasionally	Once daily	Twice daily
Three times daily	Four times daily	Other
		If Other, specify
FOR SITE STAFF ONLY: SIGNED:	PRINT NAME:	DATE://

APPENDIX 8. Acute Symptoms Chart

Acute Symptoms Questionnaire									
ΗΟΡΟΝ									
Project		Trial Number		F	atient Initials				
Please indicate your experience of th cling the appropriate answer. If you s					irgery by cir-				
EXAMPLE (if you are experiencing quite a lot of pain then you would circle number 4 - "quite a lot")	None	A little	Some	Quite a lot	A lot				
Pain	1	2	3	4	5				
Day 1 (day after surgery)	None	A little	Some	Quite a lot	A lot				
Pain	1	2	3	4	5				
Swelling	1	2	3	4	5				
Bleeding	1	2	3	4	5				
Difficulty in opening mouth	1	2	3	4	5				
Difficulty in eating normal diet	1	2	3	4	5				
Day 2	None	A little	Some	Quite a lot	A lot				
Pain	1	2	3	4	5				
Swelling	1	2	3	4	5				
Bleeding	1	2	3	4	5				
Difficulty in opening mouth	1	2	3	4	5				
Difficulty in eating normal diet	1	2	3	4	5				
Day 3	None	A little	Some	Quite a lot	A lot				
Pain	1	2	3	4	5				
Swelling	1	2	3	4	5				
Bleeding	1	2	3	4	5				
Difficulty in opening mouth	1	2	3	4	5				
Difficulty in eating normal diet	1	2	3	4	5				
Day 4	None	A little	Some	Quite a lot	A lot				
Pain	1	2	3	4	5				
Swelling	1	2	3	4	5				
Bleeding	1	2	3	4	5				
Difficulty in opening mouth	1	2	3	4	5				
Difficulty in eating normal diet	1	2	3	4	5				

Page 1 of 2

Acut	te Symp	toms Que	stionnai	re	
H O P O N					
Project		Trial Numb	er	Pa	tient Initials
Day 5	None	A little	Some	Quite a lot	A lot
Pain	1	2	3	4	5
Swelling	1	2	3	4	5
Bleeding	1	2	3	4	5
Difficulty in opening mouth	1	2	3	4	5
Difficulty in eating normal diet	1	2	3	4	5
Day 6	None	A little	Some	Quite a lot	A lot
Pain	1	2	3	4	5
Swelling	1	2	3	4	5
Bleeding	1	2	3	4	5
Difficulty in opening mouth	1	2	3	4	5
Difficulty in eating normal diet	1	2	3	4	5
Day 7	None	A little	Some	Quite a lot	A lot
Pain	1	2	3	4	5
Swelling	1	2	3	4	5
Bleeding	1	2	3	4	5
Difficulty in opening mouth	1	2	3	4	5

At day 8, one week after your surgery, are you comfortable and able to eat normally?

No

Yes

Page 2 of 2

APPENDIX 9. Case for change to definition of the primary endpoint: HOPON trial.

Case for change to definition of the primary endpoint: HOPON trial.

In the current protocol, the primary endpoint of the trial simply relates to the presence / absence of osteoradionecrosis. This is described in textbooks and research articles over the previous 3 decades as:

"Exposed and necrotic bone associated with ulcerated or necrotic surrounding soft tissue which persists for greater than three months in an area that had been previously irradiated (not caused by tumour recurrence)."^{1,2}

This description has been adopted as closely as possible for a definition of the primary endpoint: that if at 6 months, there is incomplete mucosal healing with exposed bone the case is described as ORN, if there is complete bony healing without exposed bone it is not ORN.

Upon seeing patients at their 6/12 primary endpoint, and further on review of blinded images of cases, the HOPON team noted a small but significant number of cases where there was near total or total mucosal healing associated with minor bone spicules. In clinical practice the investigators would not regard them as ORN, they are not symptomatic, and they probably reflect delayed healing rather than progressive necrosis, although the latter is conjecture.

The HOPON team were concerned that classifying these cases as either "healed" or "ORN" was unsatisfactory. They felt that an additional class "minor bone spicules" should be used to enhance clarity, where the total area of exposed bone <4 x5mm, or 10x 2mm ie. <20mm². For the purpose of the HOPON trial, minor bone spicules will be analysed as if healed (grouped with "not ORN"), as the clinical significance is equivalent to this. There was a concern that if the PI were reporting as ORN, and by chance they were skewed to one or other arm of the trial, this would unfavourably distort the results, possibly undermining the whole trial. If minor bone spicules were seen equally distributed in both arms of the trial, then this would likely not affect the result, but would lead to a misleading, high, incidence of ORN for this cohort of patients. As the incidence of ORN after surgery is unknown, the overall level of risk of developing ORN should be accurately reported as an important outcome of HOPON.

Because the trial is powered on clinically significant ORN (as has, we presume, been reported in previous audits, cohorts and trials), this has no impact on the differences between the arms necessary to change practice, the power calculation, or the sample size.

The classification for the purposes of the HOPON trial will therefore be: Not ORN: mucosa healed or minor bone spicules (<20mm²); ORN present & further subdivided to Notani³ 1 (& >20mm²) Notani 2 or Notani 3. Having encountered this problem, we feel it would be worth publishing this modified scoring system for use in classifying ORN in clinical trials. The problem arises in taking a reasonable working textbook definition of a condition and too literally applying it as a primary endpoint on a clinical trial.

- M. Harris. The conservative management of osteoradionecrosis of the mandible with ultrasound therapy. Br J Oral Maxillofac Surg, 30 (1992), pp. 313–318
- Shaw RJ, Dhanda J. Hyperbaric oxygen in the management of late radiation injury to the head and neck. Part I: treatment. Br J Oral Maxillofac Surg. 2011 Jan;49(1):2-8.

 Notani K, Yamazaki Y, Kitada H, Sakakibara N, Fukuda H, Omori K, Nakamura M. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy.. Head Neck. 2003 Mar;25(3):181

APPENDIX 10: Procedure for reviewing HOPON Photographs and OPT images at 6 month following surgery

Introduction

This document describes the procedure for reviewing the primary endpoint for HOPON and deriving a "definitive" outcome to be used for the DMC and Final analyses.

Procedure

Upon receipt of the 6 month HOPON photographs and OPT images at LCTU, the HOPON Trial Coordinator will send the photographs and OPT images to the CI (Prof. Richard Shaw) and CC (Mr. Chris Butterworth) simultaneously but separately for a review. If 6 month images are not received, please see below.

The CI and CC will then review the images and reach an agreement on the assessment of ORN. If they cannot reach an agreement, please see below. If the 6 month images are inadequate (in that they alone are of insufficient quality to assess ORN), then the result of the 3 and 12 month images will be used to base their decision (eg if ORN is present at 3 months and 12 months it will be assumed present at 6 months). If both of their reviews are the same as the site Principal Investigator (PI), then the final ORN assessment will be that of the PI.

If the CI and CC's consensus assessment differs from the site PI, or if the CI & CC cannot agree a consensus diagnosis then the TC will liaise with the relevant site PI/co-investigator and make arrangements to discuss the relevant patient with the CI and CC. If the CI, CC and site local investigator reach an agreement on the assessment of ORN taking into account the 3 and 12 month results (if available), then the final ORN diagnosis will be determined. If agreement is not reached, a majority vote will be taken.

If the blinded review is not possible for example due to lack of/poor quality patient images, then the local Investigator's assessment will be used to determine the final outcome and the observation will be down weighted in the statistical analysis. Instances of exposed bone which are less than 20mm squared will not be considered as ORN, but classed as "minor bone spicules".

The table below will be distributed separately to CI and CC and their separate diagnoses entered before merging with each other and the 3 month, 6 month and 12 month PI diagnoses.

The CC and CI will complete the following columns (listed by A-I):

- 1) E and F
- 2) They will return their assessments to the TC
- 3) The TC will merge the results into a single table
- 4) The TC will complete column G
- 5) The TC will complete columns A to D
- 6) If there is no consensus between the CI and CC, the CI and CC will be informed and asked to discuss the individual cases taking into account the local investigator's data in columns B and D
- 7) If there is a consensus between the CI and CC, but not the local investigator, or if the image quality is insufficient to allow an assessment to be made, this will be shown in column G and the TC will then contact the local investigator to arrange discussions between the local investigator, CI and CC
- 8) Once a consensus is reached by all parties, this will be reflected in column I
- 9) Column H will be completed in cases were the local investigator revises their original 6 month decision to match that of the CI and CC, using the classifications shown in Table B below
- 10) If a consensus is not reached, a majority decision will be taken and column I will be update
- 11) If the blinded review is not possible for example due to lack of/poor quality patient images, then the local Investigator's assessment will be used to determine the final outcome and the observation. This will be indicated in column I and J
- 12) The data shown on columns A, I and J will be used to update MACRO


TABLE A:

A Patient no	B PI 3mth	C PI 6mth (Primar y EP)	D PI 12mth	E CI review 6m	F CC revie w 6m	G 3 Way Discuss ion (y/n)	H Revised PI diagnosis (if applies)	I Final diagnosi s	J Final diagnosis based on original PI assessmen t only (y/n)
		Mucosal healing		1	2	yes		1	
		Notani 1							
		Notani 2							
		Notani 3							

TABLE B

Diagnoses will be coded as follows:

Mucosal healing	1
Minor bone	2
spicules	
Notani 1	3
Notani 2	4
Notani 3	5



APPENDIX 11: Late follow up of MBS (Minor Bone Spicules)

Versio	n 1-09/01/2017 HC	OPON Late Follow Up CR	Page 1 of 1
Н		Trial Number	Patient Initials
Lat	te follow up of MBS	(Minor Bone Spicules)	
	ction - diagnosis of MBS at 1. th visit was omitted)	2 month HOPON trial visit (or last recorded tric	al visit in the event that the 12
1.	Has the patient receive	d ongoing clinical review since completi	ng HOPON assessments?
	No If "No" please go to the final off the form.	Yes step of posting	
2.	Can it be determined from healed or had exposed No If "No" please go to the final off the form.	Yes	HOPON trial were fully
Ple	ase complete one row of this to	able for each appointment since the HOPON 12	month trial visit.
	tere were more than one area tor Bone Spicule (MBS) / Nota	of exposed bone, please state the <u>worst severity</u> mi 1 / Notani 2 / Notani 3	as per the grading: Healed /
Da	te of assessment	Result* Please tick ONLY one box for each date	
	/ / ddmm/0000	Healed MBS Notani 1	Notani 2 Notani 3

da/mm/yyyy					
	Healed	MBS	Notani 1	Notani	2 Notani 3
dd/mm/yyyy	Healed	MBS	Notani 1	Notani	2 Notani 3
da/mm/yyyy	Healed	MBS	Notani 1	Notani	2 Notani 3
da/mm/yyyy	Healed	MBS	Notani 1	Notani	2 Notani 3

*Definition:

'Healed' - full mucosal / skin healing in area of previous surgery

'MBS' - Minor Bone Spicules - <=20mm2 exposed bone (i.e. 4 x 5mm, or 2 x 10mm)

Notani 1' - Exposed bone, extent limited to dentoalveolar bone <u>Notani 2' - Exposed bone, limited to area above ID canal</u> <u>Notani 3' - Exposed bone, full thickness of mandible, or pathological fracture, or extra-oral fistula.</u>

Please post the completed form to the HOPON Trial Coordinator:

CRUK LCTU, U	niversity of l	_iverpool,	1st floor	Block C,	Waterhouse	Building,
3 Brownlow Str	eet, Liverpo	ol L69 3GL	_			

FOR SITE STAFF ONLY: SIGNED:	PRINT NAME:	DATE://

APPENDIX 12: Late follow up of implant survival

H O P O N Project Trial Number Patient Initials
Late follow up of implant survival
Selection – patients in HOPON trial – eligibility was placement of implants
1. How many implants were placed in the mandible?
2. Were any implants recorded as lost during HOPON follow-up?
No Yes
If "No" then please go to step 3 If "Yes" then please specify dates implants lost and return form
dd/mm/yyyy
da/mm/yyyy
dd/mm/yyyy
dd/mm/yyyy
3. Has the patient received ongoing clinical review since completing HOPON assessments?
No Yes
If "No" please go to the final step of posting off the form.
4. Please give date of most recent review since completing HOPON assessments
// dd/mm/yyyy
5. Do patient records show if any implants have been lost?
No Yes
If "No" please go to the final step of posting off the form.
6. Please give dates on which implants were lost since completing HOPON assessments
dd/mm/yyyy
dd/mm/yyyy
dd/mm/yyyy
Please post the completed form to the HOPON Trial Coordinator, CRUK LCTU, University of Liverpool
1st floor Block C, Waterhouse Building, 3 Brownlow Street, Liverpool L69 3GL
FOR SITE STAFF ONLY: SIGNED: PRINT NAME: DATE:/